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 The expanded use of combination antiretroviral therapy (cART) has dramatically 
enhanced the quality of care and life expectancy of HIV-positive individuals. However, 
incomplete adherence and treatment interruptions (TIs) due to treatment fatigue, side 
effects and cART toxicities have emerged as major challenges to the full realization of 
the therapeutic promise of cART. Despite the relatively high frequency of TIs, their 
determinants and outcomes are still not well-characterized.  
 
Methods  
 Trends, predictors and consequences of treatment interruption (TI) and 
resumption in two study populations were estimated. First, the Longitudinal 
Investigations into Supportive and Ancillary health services (LISA) is a cross-sectional 
study of hard-to-reach individuals on cART in British Columbia. Between 2007 and 
2010, 1000 participants were interviewed about sociodemographic and clinical factors. 
Using pharmacy recording, TIs were defined as a patient-initiated interruption in 
treatment of at least 90 days during the 12 months preceding or following the study 
interview. Multivariable logistic regression was used to identify factors associated with 
treatment interruption. The second study, the Canadian Observational Cohort (CANOC) 
collaboration, is composed of treatment-naïve HIV-positive individuals who initiated 
cART between 2000-2011. TIs were defined as interruptions in cART for a period of at 
least 90 days. Cox proportional hazards regression was used to identify determinants and 





 Of 768 participants included in the LISA study, 15% had a TI recorded during the 
study window. In multivariable analysis, TIs were significantly associated with current 
illicit drug use (adjusted odds ratio (aOR): 1.68, 95% confidence interval (CI): 1.05-
2.68); <95% adherence in the first year of treatment (aOR: 2.68, 95% CI: 1.67-4.12); 
living with more than one person (aOR: 1.95; 95% CI: 1.22-3.14) or on the street (aOR: 
5.08, 95% CI: 1.72-14.99) compared to living alone; poor perception of overall health 
(aOR: 1.64 95% CI: 1.05-2.55); being unemployed (aOR: 2.22, 95% CI: 1.16-4.23); and 
younger age at interview (aOR: 0.57, 95% CI: 0.44-0.75, per 10 year increment). 
A total of 7,633 CANOC participants initiating cART between 2000 and 2011, of 
whom 1,860 (24.5%) had at least one TI ≥90 days. The prevalence of TI in the first 
calendar year of cART decreased by half over the study period. Predictors of a first TI 
were female sex (adjusted hazard ratio (aHR): 1.59, 95% CI: 1.33-1.92), Aboriginal 
ancestry (aHR: 1.67, 1.27-2.20), a history of injecting drug use (aHR: 1.43, CI: 1.09-
1.89), hepatitis C antibody seropositivity (aHR: 2.17, CI: 1.68-2.79), a baseline CD4 cell 
count above 350 cells/mm3 versus less than 200 cells/mm3 (aHR: 1.46, CI: 1.17-1.81) and 
use of zidovudine versus tenofovir in the initial cART regimen (aHR: 2.47, CI: 1.92-
3.20). Factors protective against TI were older age (aHR: 0.79, CI: 0.73-0.87), higher 
HIV plasma viral load (log10) (aHR: 0.87, CI: 0.78-0.97) and residence in Ontario (aHR: 
0.55, CI: 0.43-0.70) or Quebec (aHR: 0.42, CI: 0.31-0.57) versus British Columbia (BC). 
Factors predicting resumption of treatment after a first TI included male sex, residence in 
BC, older age, more recent cART initiation and a CD4 cell count <200 cells/mm3 at 
iii 
 
cART initiation (all p<0.05). TIs were associated with increased risk of mortality (aHR: 
1.79, CI: (1.49-2.16)) after adjusting for socio-demographic and clinical factors.  
 
Conclusions 
 Despite significant improvements in cART since its advent and the decreasing 
prevalence of TIs, gaps in treatment remain relatively common. As cART is propagated 
at increasing levels globally, and the impetus to provide treatment earlier in the course of 
HIV infection for individual and public health benefits gains momentum, ensuring 
continuity of treatment becomes even more vital. Strategies to support continuous HIV 
treatment are needed to maximize the benefits of cART. 
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1.1 Specific Aims 
 
  There are 71,300 people currently living with HIV/AIDS in Canada. As 
individuals with HIV live longer, thereby spending more time on treatment, it is 
important to emphasize and facilitate continuity of treatment. Moreover, characteristics of 
individuals with poor engagement in care and the effect of interruptions on HIV disease 
progression should be ascertained. As the paradigm of “treatment as prevention” gains 
traction and treatment earlier in the course of disease is being encouraged, it is 
particularly timely that we seek to understand how to keep individuals engaged in 
treatment. Furthermore, new recommendations from the World Health Organization 
expand the eligibility of HIV-positive individuals initiating cART from 350 to 500 
cells/mm3, rendering the facilitation of continuous, lifelong therapy even more essential. 
The overall objective of this study is to identify the determinants and consequences of 
interrupted access to treatment ≥ three months in order to design strategies to optimize 
the benefits of long-term, continuous treatment in a setting of universal access to care in 
Canada. Two studies will be used to assess this objective: the Canadian Observational 
Cohort (CANOC) collaboration, the largest HIV treatment cohort in Canada, composed 
of antiretroviral naïve HIV-positive individuals who have initiated cART since 2000, and 
the Longitudinal Investigation into Supportive and Ancillary Health Services (LISA) 
study, a provincial study of 1,000 participants that will be used to explore socio-
behavioral and clinical factors associated with TIs. The aims are as follows:   
 




Hypothesis: Individuals dealing with concurrent health issues, lack of access to care and 
competing life demands (addictions, substandard housing and depression) will be more 
likely to interrupt treatment. 
 
Aim 2: Identify demographic, clinical and laboratory factors that predict time to first 
treatment interruption following ART initiation, as well as factors associated with time to 
resumption of ART following first interruption. 
Hypothesis: The prevalence of TIs will decrease over time. 
 
Aim 3: Investigate the impact of unstructured treatment interruption on mortality. 
Hypothesis: Individuals who interrupt treatment will have higher mortality than those 
who do not. 
 Aim 1 will be evaluated in the LISA study, while Aims 2 and 3 will be 
investigated in CANOC. The new knowledge generated by this research will serve to 
identify modifiable factors related to treatment interruption that may be used to inform 




 In the 30 years since HIV was discovered as the virus causing AIDS, our capacity 
to fight the scourge that has claimed 36 million lives globally [1] since its advent has 
been revolutionized. While a cure for HIV remains out of reach, combination 
antiretroviral therapy, or cART, has improved treatment to the degree that a young adult 
on cART without pre-existing conditions has the potential to live as long as his HIV-




positive individuals to live  relatively unmarred by the once-unavoidable ravages of HIV, 
their viability in controlling viremia and in achieving the best possible patient outcomes 
is predicated on daily, lifelong use. As one patient eloquently framed the issue, "HIV is 
not a death sentence, but it's a life sentence. You'll be taking pills forever, going to the 
doctor and fighting for insurance forever [3]."  
 The dissertation has three aims related to trends in the continuity of HIV 
treatment and the gaps in treatment that have the potential to derail the gains achieved in 
life expectancy and quality of life. The first aim is to identify predictors of TIs in the era 
of modern cART, often characterized as the period beginning in 2000. Secondly, the 
dissertation aims to determine what factors predict resumption of treatment after a first 
TI. The final aim is to characterize the effect of treatment interruptions (TIs) on all-cause 
mortality. To address these aims I will use data from the aforementioned Canadian 
studies undertaken in the era of modern cART. 
 
1.3 HIV in Canada 
 
 At the end of 2011, there were an estimated 71,300 (58,600-84,000) individuals 
living with HIV in Canada (including those with AIDS), an increase of about 11% from 
2008 [4]. Men who have sex with men (MSM) constitute the largest group of individuals, 
with 47% of the total proportion, while heterosexual individuals from non-endemic 
countries represent 18% and  injection drug users represent 17%. HIV prevalence has 
continued to increase and there are approximately 3,000 new infections a year. 
Individuals of Aboriginal descent (including Métis, First Nations and Inuit) are 




composing only 4% of the Canadian population, Aboriginal people represented 12% of 
new HIV infections in Canada in 2011 (of those cases with reported ethnicity) [4]. As in 
many parts of the world, HIV in Canada targets society’s most vulnerable groups; those 
who are victims of structural inequalities that put them at higher risk of infection. The 
same factors that make these groups vulnerable to infection with HIV can also prevent 
them from both accessing care and treatment in a timely manner and consistently 
engaging in care, causing worse outcomes in both morbidity and mortality [5-7]. 
 Canadians have had relatively good access to HIV/AIDS medication since they 
were introduced in 1986. A national health insurance program provides affordable access 
to hospital and physician services and subsidizes cART [8]. All antiretroviral drugs must 
go through clinical trials and prove their safety and effectiveness to Health Canada before 
being licensed. Provincial and territorial programs for HIV/AIDS medications differ, 
ranging from complete coverage as in British Columbia, to special coverage categories, 
or coverage through programs with income-based deductibles.   
 
1.4 History of treatment interruptions 
 
 Until 2006, structured treatment interruptions or “drug holidays” were 
occasionally prescribed by physicians in order to minimize treatment-related side effects, 
improve patient quality of life and decrease the costs of HIV treatment and care [9]. 
While the life-saving and life-extending benefits of antiretroviral therapy are manifest, 
treatment fatigue is a common phenomenon and can lead to interrupted therapy. Prior to 
2006, clinicians and researchers investigated the option of physician-directed TIs, on the 




prescribed, physicians should prescribe the interruptions based on medical criteria and 
monitor patients. However, following the results of the Strategies for Management of 
Antiretroviral Therapy (SMART) trial in which intermittent therapy of HIV (versus 
continuous therapy) led to statistically significantly increased risk of HIV disease 
progression, severe complications and death, the use of treatment interruptions in the 
management of HIV-positive individuals were no longer recommended [10-12]. 
 Two types of periodic structured, or supervised, treatment interruptions have been 
evaluated: a) CD4 cell count-guided and b) time-defined. The former strategy, used in the 
SMART trial, uses intermittent therapy in which CD4 cell counts determine the 
thresholds for starting and stopping treatment. The latter strategy sets predetermined 
interruptions in treatment, such as stopping treatment on weekends or alternating months 
on treatment. This dissertation will focus primarily on unstructured interruptions as those 
most relevant in a period of modern cART; however, evidence gleaned from both types 
of interruptions will be described in the following sections to provide a comprehensive 
illustration of research related to TIs. 
 
1.5 Prevalence of unstructured antiretroviral treatment interruption 
 
 Studies vary in their definitions of treatment interruption – some consider a 
stoppage in treatment intake of a single day to be an interruption, while others use longer 
periods to denote an interruption. Thus, considerable variability among studies exists in 
the recording of interruptions, making comparisons challenging. Moreover, studies that 
occurred before 2006 often include individuals who interrupted treatment based on their 




 Considering studies examining longer unstructured treatment interruptions, a 
Swiss cohort found that 28% of individuals interrupted therapy between one and three 
months [13]. A large European study determined that after three years, 16% of patients 
had interrupted treatment for three months or longer [14], while 23% of participants 
interrupted for at least three months in an Italian study [15]. Research from the British 
Columbia Centre for Excellence in HIV/AIDS (BC-CfE) has also identified that almost 
40% of patients, followed for a median of 3.3 years, had experienced at least one TI of at 
least three months [16], while a study of injecting drug users in Baltimore reported that 
78% of participants had at least one TI of six months or longer, and 20% never resumed 
cART [17].   
 Assessing studies with shorter defined TIs, a multi-centre study in the United 
States found that 30% of participants had interrupted treatment for more than seven days 
[18] while a Spanish cohort study observed that 43% of participants had TI longer than 3 
days [19]. A study examining cohorts in Europe, Israel and Argentina reported an 
incidence rate of 6.0 per 100 person years of follow up [14]. Lastly, a systematic review 
of TIs in both developed and developing countries and cognizant of the many definitions 
of TIs ascribed by different studies, reported a median proportion of patients interrupting 
cART of 23% (Interquartile range: 15-48) [20].  
 
1.6 Risk factors predicting unstructured interruptions in treatment 
 
 A number of studies have elucidated predictors of treatment interruption in a 
developed world context. Demographically, interrupters are more likely to be female 




are more likely to have suboptimal adherence [18]; and have a history of injection drug 
use [13, 16, 21]. In terms of clinically relevant predictors, treatment interrupters are more 
likely to be depressed [18]; have a shorter duration of cART use [14, 18]; higher baseline 
CD4 cell counts [13, 14, 16]; higher HIV plasma viral loads [13, 14, 18, 21]; and 
hepatitis C co-infection [16]. They are also more likely to be taking certain antiretroviral 
regimens [14, 16]. A study of injection drug users in British Columbia found that recent 
incarceration, lack of faith in the benefits of cART, and poor efficacy expectations 
(ability to manage treatment schedules and side effects) were independently associated 
with cART discontinuation [22].  
 As yet, there is limited research examining treatment interruption in antiretroviral-
naïve cART initiators and patients initiating treatment in the modern cART era, which is 
characterized by more tolerable and convenient cART regimens. Moreover, few studies 
investigate the frequency and impact of interruptions in the period occurring after 
interruptions were no longer recommended (2006 onwards). Similarly, the epidemiology 
of treatment interruption in a Canadian context has not been well elucidated.  
 
1.7 Factors association with resumption of treatment 
 
Structured TI 
 A randomized trial by the Swiss-Thai-Australia Treatment Interruption Trial 
(Staccato) group described factors associated with re-starting cART in the scheduled 
interruption trial arm. These were lower CD4 cell count before cART initiation, lower 




of note, 50% of individuals in the interrupted arm restarted cART within 18 weeks of 
randomization and after 100 weeks, 75% of individuals had been re-engaged in treatment.  
Unstructured TI 
 A South African study found that women, older individuals, and shorter duration 
of interruption predicted resumption of treatment [24]. A study in BC observed that 71% 
(488) of patients who interrupted therapy restarted, with males and individuals with a 
history of AIDS-defining illness more likely to restart. Those less likely to re-engage in 
therapy had higher CD4 cell counts at the time of interruption [16]; this is especially 
problematic in light of the fact that lifelong cART is now being advocated for individuals 
with CD4 counts ≤ 500 cells/mm3 [25]. Another study defining TIs as a gap of three 
months or greater reported that 76% of patients restarted treatment; however, in this 
study, 50% of individuals were on a structured interruption [26]. 
 
1.8 Detrimental effects of treatment interruptions 
 
Structured 
 As the SMART study demonstrated, there are severe and detrimental sequelae for 
individual as well as public health outcomes associated with interruptions in antiretroviral 
treatment. TIs result in significantly heightened risk of opportunistic infection and death 
from any cause compared to continuous antiretroviral therapy [27]. They also lead to 
plasma viral load rebound [28, 29], potentially increased risk of transmitting virus to 
others [30], risk of acute viral infection [26, 29], which was found in 6% of participants 
who interrupted treatment in the Staccato trial [23], and the development of new 




was an increased risk of cardiovascular, hepatic and renal disease in the intermittent 
treatment group compared to the group receiving continuous treatment [11]. Furthermore, 
a similar large-scale study showed that the increased risk did not abate once treatment 
was re-initiated [36]. 
 A Cochrane review of structured treatment interruptions in chronically 
unsuppressed HIV-positive adults indicated that interruptions are harmful [37]. A similar 
Cochrane review examining virologically suppressed adults found that time-defined 
interruption strategies led to the development of drug resistance while CD4 cell count-
guided approaches reduced costs and improved tolerability of regimens but led to 
concerns about long-term safety related to immunological, virological and clinical 
outcomes [33]. Although interruptions in treatment are considered by some to enhance 
health-related quality of life, a randomized controlled trial refuted this observation [38]. 
Unstructured 
 In studies specifically examining the effects of unstructured treatment 
interruptions, similar detrimental effects have been found. For example, a large cohort 
collaboration studying patients in Europe, Israel and Argentina observed a risk of AIDS 
and death more than two-fold greater in individuals who interrupted treatment relative to 
those who did not [14]. There is little consensus determining what length of interruption 
leads to clinically significant consequences. Some studies have found that rebound in 
viral load before 7 days after stopping cART is uncommon [39, 40]; however, other 
findings examining viral uncovered that HIV plasma viral load levels returned to > 500 
copies/mL within 6 to 15 days (median 10 days) and approached or exceeded pre-therapy 




consequence of TI, Moore et al. found that individuals who interrupted treatment more 
than 230 days were at higher risk of mortality than those who interrupted less than 230 
days [16]. 
 However, some studies found no detrimental effect of TIs. Results from the Swiss 
Cohort Study examining short TIs of one to three months found that TIs did not 
statistically significantly raise the risk of HIV-related morbidity and mortality [13]; 
similarly, a factorial randomized trial evaluating two types of treatment (standard versus 
intensified cART) as well as immediate retreatment or a 12-week structured TI for 
patients with cART failure did not find significant differences in clinical outcomes 
between the groups [41]. A small Thai trial also did not observe statistically significant 
differences in clinical outcomes between structured TI arms and continuous treatment, 
though the study had a short follow-up period [42]. 
 
1.9 Relevance of the current research 
 
 This dissertation first seeks to establish whether TIs are detrimental in the 
Canadian population in the context of modern cART. Second, in this era of modern 
cART, with ostensibly fewer barriers to treatment as drug-related side effects and pill 
burden decrease, do individuals on HIV treatment continue to interrupt treatment? If so, 
who is most likely to interrupt, and why? Which individuals are more likely to resume 
cART after a TI? Lastly, does resumption of cART after TI confer any survival benefits, 
and if yes, to what degree? Drawing on several available datasets, we will determine 




 One motivation for the study is to reproduce the results of randomized trials 
examining TIs in actuality rather than in controlled environment. David Savitz describes 
how certain phenomena are impossible to simulate in the laboratory [43]; similarly, 
randomized controlled trials, such as the SMART trial, while the gold standard of 
research, provide better information about the efficacy (effect of periodic scheduled 
interruptions) than effectiveness (actual patterns and effects of interruptions for a patient 
outside of a trial). Although the SMART trial demonstrated that treatment interruptions 
resulted in adverse outcomes for study participants, a randomized trial does not reflect the 
real world, in which HIV-positive participants on cART have diverse reasons for 
interrupting and resuming treatment. Furthermore, a randomized trial may not produce 
the heterogeneity found outside of the “laboratory.” For instance, inclusion in the 
SMART trial required an individual to have a CD4 cell count greater than 350 cells/mm3 
within 45 days of study entry, have good health at the time of study entry and be able, in 
the clinician's opinion, to comply with the protocol, which does not mimic the population 
in treatment [11]. There is a clear impetus for non-clinical trial observations as to the 
frequency, predictors and consequences of interruptions in treatment. 
 In “The Nature of Epidemiologic Evidence,” Savitz describes how the causal 
impact of an exposure on disease (such as treatment interruption on adverse HIV 
outcomes), even when established by a reputable and well-executed study, needs to be 
assessed more than once, and in different populations, to ascertain the generalizability of 
the association and further support decision-making in public health practice and policy 
[44]. While one can have confidence that measures of association found in the SMART 




modern cART regimens, for example – this confidence does not preclude the 
implementation of a similar study. In effect, the basis for the scientific method is 
repeatability and reproducibility. 
 Now that the benefits of antiretroviral treatment in improving survival have been 
established, the focus of HIV research in the developed world has shifted from a mindset 
of not only saving lives but also ensuring the quality of life of HIV-positive individuals. 
Until a veritable cure for the disease can be developed, antiretroviral treatment represents 
the optimal approach for managing HIV care. Thus, establishing how to maximize the 
effect of this treatment is a necessary and vital area of epidemiologic research addressing 
HIV. 
 
1.10 Conceptual framework and directed acyclic graph (DAG) 
 
 Gardner et al. created a model examining the continuum of HIV engagement in 
care in the United States. He suggests that HIV treatment and care can be conceptualized 
as a continuum, from initial acquisition of HIV to successful engagement in care, 
characterized by a high level of adherence and an undetectable HIV plasma viral load 
[45]. Each step in the aptly named “cascade” must be monitored since individuals exit the 
cascade at each step. For instance, only 75% of individuals who were diagnosed in the 
United States as HIV-positive remained linked to HIV care, and less than 20% of HIV-
positive individuals were adherent with undetectable HIV plasma viral load [45]. Thus, 
there are numerous points at which to intervene in the cascade, and efforts at each stage 
are needed to best ensure that individuals living with HIV have the best possible 




examining interruptions in treatment, since individuals who interrupt treatment are not 
retained. Gardner’s review estimates that as high as 50% of known HIV-positive 
individuals are not engaged in regular HIV care, whether that is sustained access to 
antiretroviral therapy, prophylactic medications or other medical services [45]. 
  Individuals who are intermittent or episodic users (defined in this study as those 
with gaps greater than or equal to three months) are hypothesized to be different from 
continuous users (those who do not have gaps, although who may not have perfect 
adherence). That is, those who take their pills inconsistently (poor adherence) are 
different from those who discontinue all antiretroviral therapy for sustained periods of 
time. This latter concept has been described as medication persistence, defined as “the 
duration of time from initiation to discontinuation of treatment” [46] or “the duration 
during which a patient remains on a prescribed therapy” in contrast to adherence, which 
is the “percentage of patient behavior to a prescribed therapy” [47]. However, medication 
persistence differs from TI because the concept of persistence precludes modifications of 
a regimen, while individuals can simplify their regimen and not be categorized as a TI. 
 The social ecological framework has been applied by a number of researchers to 
explore health-seeking behavior in the context of both discontinuations of antiretroviral 
therapy as well as adherence [48, 49]. This framework describes human behavior as a 
function of personal and environmental (social, economic, political, health system) 
factors [49]. Using facets from this framework, the Gardner model and knowledge of the 
literature on TIs, a directed acyclic graph (DAG) was developed that summarizes 
assumptions about how the variables in the analysis are causally related, as shown in 




about HIV treatment may lead to differential rates of treatment interruption and 
differences in disease progression and mortality. In particular, injection drug users may 
be most at risk for interrupting treatment due to concurrent health issues and competing 
life demands, such as poor housing. 
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1.11 Study Population 
 
1.11.1 Longitudinal Investigation into Supportive and Ancillary Health Services (LISA) 
 The recruitment period for the LISA cohort occurred from July 2007 to January 
2010. Participants were recruited through letters distributed by their physicians, which 
were received when patients filled their cART prescription at their pharmacy, through 
word-of-mouth and advertisements at HIV/AIDS service organizations in BC. To be 
eligible for LISA, participants had to be at least 19 years of age and antiretroviral naïve 
prior to initiating highly active antiretroviral therapy. Once screened, eligible participants 
provided informed consent in writing. Cross-sectional interviews were confidential and 
took approximately 45 minutes to complete. A $20 honorarium was provided to all 
participants as compensation for their time. Interviews occurred at various HIV/AIDS 
organizations across British Columbia such as AIDS Vancouver Island and Vancouver 
Native Health.  
 Cross-sectional questionnaire data was linked with clinical data (e.g. CD4 cell 
count, HIV viral load and treatment adherence) obtained through longitudinal linkages 
with the Drug Treatment Program at the BC-CfE, which is mandated to distribute 
antiretroviral medications free of charge to all eligible HIV-positive individuals in the 
province. Two years of enrollment for the LISA study yielded a total of 1000 
participants, of whom 83 (9%) were excluded due to problems in linking to clinical 
variables, leaving 917 as the final study sample. Ethical approval for the LISA study was 
obtained from the University of British Columbia/ Providence Health Care, Vancouver 






1.11.2 Canadian Observational Cohort Study (CANOC) 
 The CANOC collaboration provides important insights into the care and treatment 
of HIV-positive individuals on antiretroviral therapy in Canada. Of the estimated 24,000 
people on HIV treatment in the provinces of British Columbia, Ontario and Quebec, 
nearly a third are currently captured in cohorts that constitute CANOC. As of October 
2011, there are 7,473 men and women in CANOC. In comparison to the Canadian 
population in 2011, CANOC participants are older (median age 41 vs. 40 years) and more 
likely to be male (81.0% vs. 49.6%), which reflects the HIV population on therapy. 
Contributing cohorts must have at least 100 active HIV-positive participants who meet 
the following eligibility criteria: documented HIV infection, residence in Canada, aged 
18 years and over, initiation of three or more antiretroviral drugs for the first time (i.e. 
ART-naïve cART start) after January 1, 2000, and a viral load measurement and CD4 cell 
count within six months of the start of therapy. All participating cohorts have received 
approval from their institutional ethics boards to contribute non-nominal (a study identity 
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CORRELATES OF HIV TREATMENT INTERRUPTION AMONG 








Objectives: In British Columbia (BC), persistent gaps exist in the care and treatment of 
HIV-positive individuals. Treatment interruptions (TIs) limit the therapeutic success of 
combination antiretroviral therapy (cART) and are associated with higher morbidity and 
mortality. HIV-positive individuals dealing with concurrent health issues, access 
challenges and competing life demands are hypothesized to be more likely to interrupt 
treatment. 
 
Methods: The Longitudinal Investigations into Supportive and Ancillary health services 
(LISA) Project is a cross-sectional study of hard-to-reach individuals on cART in BC. 
Between 2007 and 2010, information was collected from 1000 participants on behavioral, 
psychosocial, health services utilization and other clinically relevant factors. Using 
pharmacy recording, TIs were defined as a patient-initiated interruption in treatment of at 
least 90 consecutive days during the 12 months preceding or following the study 
interview. Multivariable logistic regression was used to identify factors associated with 
TI. 
 
Results: Of 768 participants included in the study, 15% had a TI recorded in the 24 
month study window. In the multivariable model, TIs were significantly associated with 
current illicit drug use (adjusted odds ratio (aOR): 1.68, 95% confidence interval [CI]: 
1.05-2.68); less than 95% adherence in the first year of treatment (aOR: 2.68, 95% CI: 
1.67-4.12); living with more than one person (aOR: 1.95; 95% CI: 1.22-3.14) or living on 




overall health (aOR: 1.64 95% CI: 1.05-2.55); being unemployed (aOR: 2.22, 95% CI: 
1.16-4.23); and younger age at interview (aOR: 0.57, 95% CI: 0.44-0.75, per 10 year 
increment). 
 
Discussion: Individuals with social vulnerabilities such as poor housing stability, 
younger age, unemployment and drug use were more likely to report TIs. In addition, 
poor adherence after treatment initiation was associated with TIs, suggesting that early 
inconsistencies in medication persistence may represent a warning sign of future TIs. 
Addressing socioeconomic barriers to treatment retention is vital for supporting the 








Once engaged in HIV care, it is imperative for HIV-positive individuals to strictly 
adhere to their prescribed medication protocol in order to maximize the life-extending 
benefits of combination antiretroviral therapy (cART). One stage of the “cascade,” as 
expounded by Gardner and colleagues [1], continuity of treatment is a vital component of 
care and the best predictor of an HIV-positive individual’s successful management of 
HIV. Treatment continuity can be examined on a continuum from measures of daily 
adherence to measures of long-term medication persistence. This distinction represents 
the difference between asking “how often” and “for how long,” respectively, with respect 
to a patient’s medication-taking practices [2]. As cART is propagated at increasing levels 
globally, and the impetus to provide treatment earlier in the course of HIV infection for 
individual and public health benefits gains momentum [3-5], ensuring continuity of 
treatment becomes even more of a pressing issue. 
Until 2006, structured treatment interruptions (TIs) or “drug holidays” were 
prescribed by physicians in order to minimize treatment-related side effects, improve 
patient quality of life and decrease the costs of HIV treatment and care [6]. These 
interruption strategies were characterized as either time-defined gaps in treatment, as in 
the STACCATO trial, or gaps based on CD4 cell count, as demonstrated in the largest 
trial examining TIs, the SMART trial [7, 8]. As evidence accumulated that these drug 
holidays led to a statistically significantly increased risk of HIV disease progression, 
severe complications and death, the use of structured TIs in the management of HIV-




Whether planned or otherwise, TIs result in a heightened risk of opportunistic 
infection [9, 11, 12], plasma viral load rebound [13, 14], increased risk of person-to-
person transmission [15, 16], risk of acute viral infection [14], found in 5.9% of 
participants with TIs in the Staccato trial [7], and the development of new resistance to 
antiretroviral agents [17-19]. Results of the SMART trial showed that there was an 
increased risk of cardiovascular, hepatic and renal disease in the intermittent treatment 
group compared to the group receiving continuous treatment [8]. Furthermore, a similar 
large-scale study showed that the increased risk did not abate once treatment was re-
initiated [20].  
Despite recognition of the detrimental effects of TIs, many studies continue to 
report on the high prevalence of TIs in their patient populations, which can range 
anywhere from 6% to 51% [21-26]. Research from British Columbia (BC) has identified 
that almost 40% of patients, followed for a median of 3.3 years, had experienced a TI 
[21]. Despite the frequency of TIs, determinants of unstructured or self-elected TIs are 
still not well-characterized [27]. This study purported to examine gaps in care of 90 






Study design and participant recruitment 
The Drug Treatment Program (DTP) at the BC Centre for Excellence in 
HIV/AIDS is mandated by the government of BC to distribute cART free of charge to 




developed by the BC Therapeutic Guideline Committee, which are consistent with 
guidelines proposed by the International AIDS Society [28], described previously at 
length [29].  
Briefly, HIV-positive individuals are enrolled in the DTP when they are first 
prescribed cART by their physicians, and are followed prospectively for clinical and 
laboratory measurements thereafter. HIV-positive individuals enrolled in the DTP 
between July 2007 and January 2010 were eligible to participate in the Longitudinal 
Investigations into Supportive and Ancillary health services (LISA) study. The LISA 
study enrolled 1,000 HIV-positive individuals over the age of 19 residing in British 
Columbia who had ever accessed cART. Study participants were actively recruited non-
randomly through letters distributed via HIV physicians and pharmacists, by word-of-
mouth and via advertisements at HIV/AIDS service organizations located throughout the 
province. Informed consent was obtained from patients prior to conducting the survey. 
The LISA study oversampled particular sub-populations in order to sufficiently power 
sub-analyses on women, people who inject drugs and people identifying as Aboriginal. 
 
Study instrument and ethical approval  
Cross-sectional socio-demographic data on LISA study participants were 
collected through a comprehensive interviewer-administered survey which captured a 
range of variables including: basic demographic data, information about housing, income, 
social support networks, mental health disorders, drug and alcohol use and quality of life 
measures. Clinical variables were obtained through longitudinal linkages with the DTP 




study was obtained from the University of British Columbia/ Providence Health Care, 
Simon Fraser University, the University of Victoria, and Vancouver Coastal Health 
Research Ethics Boards.  
 
Inclusion criteria 
In order to be included in this analysis, participants were required to have initiated 
cART at least one year prior to their interview date, which was necessary in order to 
obtain a complete measure of treatment adherence in the year prior to enrollment.  
Patients were excluded if they moved out of the province during the study period, entered 
a randomized trial, or if they had already interrupted treatment 12 months prior to the 
interview, as determined by clinical linkages to the DTP, which excluded 149 
individuals. 83 individuals who initiated treatment outside of BC and did not have a CD4 
cell count or initial regimen recorded at initiation were also excluded, leaving a sample 
size for this analysis of 768 individuals.  
 
Outcome variable  
The outcome variable, treatment interruption, was defined as a non-medically 
supervised interruption in antiretroviral treatment of at least 90 consecutive days during 
the 12 months preceding or following the study interview. Instances of medically 
supervised TIs were recorded in the provincial database and could therefore be excluded. 
Pharmacy prescription refill of cART was used to identify TIs of 90 days; that is, when 
individuals did not retrieve their prescription, they were recorded in the database as 




among studies in defining the length of a TI, a period of 90 days or longer was chosen to 
help decrease misclassification of TIs due to reporting delays or stockpiled medication.  
 
Explanatory variables 
A number of covariates were identified as possible factors that might influence TI 
occurrence. Socio-demographic variables included: age, gender, sexual orientation, 
Aboriginal ancestry, education (<high school vs. ≥high school), current employment 
status, current income (dichotomized at $15,000) and provincial income assistance. The 
survey also asked about lifetime diagnosis of a mental health disorder, lifetime 
experience of violence and abuse, and incarceration and drug use, both lifetime and 
current. Lifetime drug use was defined as having ever used cocaine, crack cocaine, 
heroin, speedball (cocaine and heroin) and methamphetamine; current was defined as 
drug use in the three months preceding the interview date. Housing was assessed by 
asking how many other people participants resided with (alone, with more than one 
person or live on the street) and the type of residence (hotel, treatment centre, shelter or 
hostel, no fixed address, prison vs. house or apartment). Depressive symptoms were 
measured using the validated 10-item Center for Epidemiological Studies Depression 
(CES-D 10) scale [30, 31] and food insecurity was measured using a modified version of 
the Radimer and Cornell questionnaire [32, 33]. Participants were also asked to report on 
their perception of their overall health (dichotomized as excellent and very good and 
good vs., poor and fair) and were asked about a series of non-mutually exclusive possible 
options for not taking cART medications, “are any of these explanations a reason you 




Clinical variables included in the analysis were CD4 cell count (cells/mm3), HIV 
viral load at time of treatment interruption (log10 copies/mL), AIDS at treatment initiation 
(yes or no), adherence in the first year of treatment (defined as taking ≥95% of prescribed 
cART in the one-year period following initiation of therapy based on pharmacy refill 
compliance) and cART regimen. A complete list of variables is included in Appendix 1. 
 
Statistical Analysis  
Bivariate analyses to compare differences between treatment interrupters and non-
interrupters were undertaken using the chi-square test for categorical variables and the 
Wilcoxon rank-sum test for continuous variables. Correlates that were statistically 
significantly associated at the univariate level (p<0.1) were candidates for inclusion in the 
multivariable logistic regression model to evaluate the independent association of 
variables with treatment interruptions. Variables that had been shown to be related to TIs, 
such as age and gender, were included in this analysis regardless of statistical 
significance, which was defined as p<0.05. A selection procedure based on the Akaike 
Information Criterion (AIC) was used to select the variables in the final model. All 
analyses were conducted using the STATA statistical package version 12.1 [34]. A 
sensitivity analysis was performed to determine whether results changed if the TI 










Of 768 participants included in the study, 117 (15%) had a recorded TI 90 days or 
longer within the 24 month window surrounding their interview date (37 prior to the 
interview and 80 subsequently), as determined by clinical linkage to the DTP. 
Demographic and clinical differences between those with and without experiences of TIs 
are presented in Table 1. Individuals with TIs were more likely to be female versus male 
(42% vs. 21%), younger (median age, interquartile range (IQR): 42 (37-41) vs. 46 (41-
52), of Aboriginal ancestry (61% vs.75%), unemployed (87% vs. 73%) and report an 
income of less than $15,000 CDN annually (74% vs. 55%). They were also significantly 
more likely to have ever been incarcerated (65% vs. 49%), to have ever injected drugs 
(78% vs. 55%) and to be using illicit drugs at the time of interview (66% vs. 50%), to 
have completed less than a high school education (50% vs. 36%) and to rate their overall 
health poorer than their counterparts who did not interrupt (48% vs. 30%). Importantly, 
those who interrupted were much more likely to report unstable housing (46% vs. 28%) 
and to cohabitate with other people (44% vs. 39%) or live on the street (7% vs. 1%) 
versus living alone. Moreover, individuals who interrupted were more likely to report 
adherence ≤95% in the first year of treatment (68% vs. 40%) or no cART at study 
interview (34% vs. 2%) (though for an interruption period less than three months) (all 
p<0.05). 
Several factors were shown to be associated with TI in multivariable analysis, as 
shown in Table 2. These included younger age at interview (per 10 year increment) 
(aOR: 0.57, 95% CI: 0.44-0.75); imperfect adherence in the first year of treatment (aOR: 
2.68, 95% CI: 1.67-4.12); unemployment (aOR: 2.22, 95% CI: 1.16-4.23); illicit drug use 




or on the street (aOR: 5.08, 95% CI: 1.72-14.99) versus alone; and having a poor 
impression of one’s overall health (aOR: 1.64 95% CI: 1.05-2.55). Female gender was 
included in the final model as a variable deemed clinically important but did not achieve 
statistical significance in the multivariable analysis. Results of the sensitivity analysis 
showed that there was no difference in the model limiting inclusion of TI events to solely 
after the interview date. 
When asked about possible reasons for missing doses of cART, participants 
reported a number of barriers and obstacles to consistent medication persistence, which 
are summarized in Figure 1. Of 768 participants, 168 (22%) responded that the question 
was not applicable to them because they always take their pills, a group that did however 
include 20 treatment interrupters. Of the remaining 600 individuals, 89% of those who 
did interrupt cited “to avoid side effects” as a reason for missing doses versus 68% of 
those who did not interrupt (p<0.001). Equal proportions of each group (66%) reported 
that the second most common reason for missing doses was that they “simply forgot.” 
Traveling or being away from home was reported by 34% of individuals who did not 
interrupt and 44% of those who did. Significantly more individuals who interrupted 
missed doses due to nausea and diarrhea (39% vs. 24%, p=0.002), running out of pills 
(32% vs. 22%, p=0.035), losing or misplacing pills (29% vs. 15%, p=0.001), and not 
having the right foods or liquids to take with the pills (28% vs. 11%, p<0.001). More than 
a quarter of those who interrupted stated that they missed doses because they “didn’t feel 
like the meds really work sometimes” (28% vs. 7%, p<0.001) and because they were 




were more likely to miss doses because they didn’t want anyone to see or notice them 






In a population of HIV-positive individuals on treatment in British Columbia, 
patient-initiated TIs continue to occur; the prevalence of TI was 15% (117/768) in the 
sample. The TI prevalence in this study is comparable to other studies examining 
unstructured TIs of similar lengths of three months or longer. For instance, a Swiss cohort 
found that 27.5% of individuals interrupted therapy between one and three months [35], 
while a large European study determined that after three years, 16% of patients had 
interrupted treatment for at least three months [36]. Results of this study are a 
conservative estimate of TIs since those who had not accessed cART at all in the 24-
month study window (possibly due to prior interruption) were excluded.  
A number of demographic and socio-behavioral factors were independently 
associated with interrupting treatment such as younger age, illicit drug use, overcrowding 
or living on the street, unemployment and a poor perception of overall health. Individuals 
dealing with concurrent issues such as a lack of stable housing or employment, as well as 
challenges related to addiction, may be unable to prioritize adherence to an HIV 
treatment regimen, resulting in periods of interruptions of cART that may compromise 
long term prognosis. Individuals with a poor perception of their overall health were more 
likely to interrupt, indicating that they may be pessimistic about the efficacy of cART in 




Similarly, a study of injecting drug users in BC found that lack of faith in the benefits of 
cART, and poor efficacy expectations (ability to manage treatment schedules and side 
effects) were independently associated with cART discontinuation [22]. 
Corroborating previous literature, this study also found that suboptimal adherence 
in the first year of ART was strongly associated with future interruptions in treatment 
[37]. This may signify that individuals who are more likely to embark on lengthy 
interruptions may effectively be identified and targeted for assistance early on in their 
course of therapy.  
With respect to factors associated with TIs, a number of findings were largely 
consistent with studies in other settings examining TIs; in particular, younger age was 
correlated with TIs in this and many other studies [21, 35, 36], which suggests that 
younger individuals may be more prone to more chaotic and dynamic lifestyles. 
Similarly, illicit drug use and hepatitis C co-infection were also associated with TIs in 
this study and in the literature [21, 35, 36]. However, this study did not find that higher 
baseline CD4 cell counts were correlated with TIs during the study period as did a 
number of other studies [21, 35, 36]; in fact, CD4 cell count at treatment initiation was 
exceedingly low for both groups. It is likely, due to our sampling strategy, that the 
population under analysis here represents a more marginalized population with lower 
variability in CD4 count than that examined in other studies. Policy-makers and 
clinicians should be especially vigilant in preventing TIs in groups of late initiators to 
prevent significantly compromised patient outcomes. 
While female gender was significantly associated with TIs in a number of studies 




In BC, a higher proportion of women acquire HIV through injecting drug use than men 
(23% vs. 10% of new diagnoses in 2011 were attributable to IDU in women vs. men [38]) 
and have demonstrated poorer adherence [39], which may result in less stability in their 
lives overall and a higher preponderance of TIs. In this study, it is likely that a higher 
proportion of men were injecting drug users than found in the general HIV-population in 
the province, leading to higher vulnerability to TIs than found for men in other studies. 
Housing status and unemployment have not been described in many studies 
examining TIs though numerous studies have found associations between unstable 
housing and suboptimal adherence [40-44] as well as treatment discontinuation [37]. It is 
conceivable that a substandard living situation or lack of income from not having a job 
could exercise a degree of stress on an individual that would preclude attention to a 
regimen of daily pills. Establishing safe and stable housing for HIV-positive individuals 
and access to employment is paramount for maintaining engagement in treatment. 
In reporting reasons for missing doses, participants cited various physical, social 
and interpersonal concerns that may act as barriers to treatment continuity, some of which 
have been described in a meta-analysis of studies in developing and developed countries 
examining poor adherence [45]. Of note, this study found that a number of individuals 
reported missing doses because they felt well. A study investigating reasons for loss to 
follow-up in a population of HIV-positive individuals in New York City similarly 
concluded that 41% left care because they “felt well” [46]. Likewise, literature on 
antibiotic compliance shows similar findings [47]. Clinicians should include information 




patients in order to prevent resistance and to ensure that patients experience the long-term 
benefits of cART.  
 
Limitations of the study  
Appreciating that many studies solely collect clinical data, LISA provides critical 
insight into complex socio-economic and demographic characteristics of HIV-positive 
individuals who have accessed treatment in BC. However, readers should be cautious 
when interpreting our results. Firstly, the study is a non-probability sample, which limits 
the generalizability of our results. Specifically, this study is subject to selection bias, as 
the modest honorarium offered to participants might have led to over-sampling of 
individuals in need of financial gain. A range of recruitment strategies were employed in 
an effort to attenuate the effect of this bias.  
Additionally, as in many studies that ask for self-reported information collected 
by interviewers, this study is vulnerable to social desirability and recall biases. As the 
study design is cross-sectional, temporal and causal relationships cannot be inferred. 
Further, by design the LISA study only includes individuals who have accessed cART, 
and thus is not representative of HIV-positive individuals who have yet to access therapy, 
who may be the most marginalized. Similar studies including all HIV-positive individuals 
in the province would be beneficial.   
This study included TIs both preceding and following the study interview in order 
to maximize the study sample. Since it is association and not causation (which 
presupposes a temporal relationship in which the exposure precedes the outcome) that is 




interview is consistent with our goal of determining correlates of interruption. Results 
from a sensitivity analysis in which only TIs recorded in the period following the 
interview date were included in the analysis were consistent with the original analysis. 
 
Conclusions and future directions 
Despite universal access to treatment across the province of British Columbia, 
interruptions in treatment among HIV-positive individuals on cART continue to be 
pervasive. Future research that includes a qualitative perspective would lead to a deeper 
understanding of the reasons that people interrupt treatment. In addition, longitudinal 
research would be able to illustrate how changes in circumstances affect treatment 
interruptions; for instance, how the loss of housing or a job might create an environment 
where the risk of an interruption is higher. Following individuals who interrupt treatment 
over time may also elucidate the long-term effects of interrupting treatment.  
In order to ensure the continuity of treatment and the best possible health 
outcomes for HIV-positive individuals, the barriers to secure, enduring, and accessible 
treatment must be addressed. Programs to assist individuals adhere to treatment should be 
developed; simultaneously, researchers, policy-makers, and clinicians alike must work to 
improve overall quality of life for individuals living with HIV so that lack of adequate 
housing, employment and addictions do not impede access to life-saving and life-
extending treatment for HIV. Only by ensuring that basic life needs are met for 
individuals living with HIV can there be an expectation of improved retention and the 
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Table 1. Characteristics of HIV-positive individuals who did and did not interrupt 








n = 651 
Treatment Interruption 
n (%) 
n = 117 
p - 
value 
Gender 768    
Male  516 (79.2) 68 (58.1) <0.001
Female  135 (20.7) 49 (41.9)  
Median age (IQR)* 768 46 (41-52) 42 (37-41) 0.001
History of IDU† 766    
yes  358 (55.1) 90 (77.6) <0.001
no  292 (44.9) 26 (22.4)  
Current illicit drug use 766    
yes  325 (50.0) 76 (65.5) 0.002
no  325 (50.0) 40 (34.5)  
Aboriginal 768    
yes  165 (25.4) 46 (39.3) 0.002
no  486 (74.7) 71 (60.7)  
Completed High School 767    
yes  418 (64.3) 58 (49.6) 0.002
no  232 (35.7) 59 (50.4)  
Earn  ≥$15,000 762    
yes  288 (44.6) 30 (25.9) <0.001
no  358 (55.4) 86 (74.1)  
Ever Incarcerated 767    
yes  315 (48.5) 76 (65.0) 0.001
no  335 (51.4) 41 (35.0)  
Currently Employed 768    
yes  177 (27.2) 15 (12.8) 0.001
no  474 (72.8) 102 (87.2)  
Unstable Housing** 767    
yes  182 (28.0) 54 (46.1) <0.001
no  468 (72.0) 63 (53.9)  
Who do you live with? 766    
Live alone  391 (60.1) 57 (49.1) <0.001
With ≥ 1 person  250 (38.5) 51 (44.0)  
Homeless  9 (1.4) 8 (6.9)  
Adherence ≥95%‡ 761    
yes  384 (59.6) 38 (32.5) <0.001
no  260 (40.4) 79 (67.5)  
* IQR= interquartile range 
†IDU= injecting drug user 
**Not living in a house or apartment 





Table 1. Characteristics of HIV-positive individuals who did and did not interrupt 









n = 651 
Treatment Interruption 
n (%) 
n = 117 
p - 
value 
Median CD4 cell count 763 210 (120-330) 215 (120-330) 0.294
at treatment initiation*      
AIDS at Baseline 768    
yes  94 (14.4) 17 (14.5) 0.980
no  557 (85.6) 100 (85.5)  
Overall Health 768    
Exc., very good, good  453 (69.6) 61 (52.1) <0.001
vs. poor, fair  198 (30.4) 56 (47.9)  
NRTI combo in cART 768    
regimen at interview     
Tenofovir/Emtricitabine  303 (46.5) 46 (39.3) <0.001
Abacavir/Lamivudine  151 (23.2) 11 (9.4)  
Tenofovir/Lamivudine  59 (9.1) 6 (5.1)  
Zidovudine/Lamivudine  20 (3.1) 3 (2.6)  
Other  104 (16.0) 11 (9.4)  
Not on cART  14 (2.2) 40 (34.2)  
Third drug in cART 768    
regimen at interview     
Nevirapine   69 (10.6) 2 (1.7) <0.001
Efavirenz  152 (23.4) 16 (13.7)  
Lopinavir  103 (15.8) 12 (10.3)  
Atazanavir  249 (38.3) 42 (35.9)  
Other  64 (9.8) 5 (4.3)  
Not on cART  14 (2.2) 40 (34.2)  
* IQR= interquartile range 
†IDU= injecting drug user 
**Not living in a house or apartment 





Table 2. Factors associated with treatment interruption of ≥90 days among 757 
LISA participants in British Columbia, Canada 
 












Female vs. Male 2.75 (1.82-4.16) <0.001 1.58 (0.99-2.52) 0.054 
Age (per 10 year increment) 0.54 (0.43-0.68) <0.001 0.57 (0.44-0.75) <0.001 
Current illicit drug use 1.90 (1.26-2.87) 0.002 1.68 (1.05-2.68) 0.030 
Aboriginal ancestry 1.91 (1.27-2.88) 0.002   
Unemployed 2.54 (1.44-4.49) 0.001 2.22 (1.16-4.23) 0.016 
Completed high school 1.83 (1.23-2.72) 0.003   
Unstable housing* 2.20 (1.47-3.29) <0.001   
Living situation     
Alone 1.00  1.00  
With many others 1.40 (0.93-2.11) 0.108 1.95 (1.22-3.14) 0.005 
On the street 6.10 (2.26-16.44) <0.001 5.08 (1.72-14.99) 0.003 
Overall health self-rated (poor, fair 
and neutral) vs. excellent and good) 
2.10 (1.41-3.13) <0.001 1.64 (1.05-2.55) 0.030 
Ever incarcerated 1.97 (1.31-2.97) 0.001   
Currently earn <$15,000 2.31 (1.48-3.59) <0.001   
Ever depressed  1.29 (0.87-1.92) 0.199   
Ever diagnosed with Hepatitis C  2.58 (1.66-4.01) <0.001   
CD4 cell count/mm3 (per 100 cell 
increase) at treatment initiation 
1.30 (0.76-2.25) 0.336   
< 95% adherence in 1st year of 
treatment 
3.07 (2.02-4.66) <0.001 2.68 (1.67-4.12) <0.001 
AIDS at treatment initiation 1.01 (0.58-1.76) 0.980   





Figure 1. Reasons for missed doses of antiretroviral medication in LISA treatment 
interrupters (N=651) and non-interrupters (N=117) 
 

















*Significant at the p<0.05 level 
**Denominator was 600 individuals for all responses except not applicable category, which included the 












PREDICTORS AND OUTCOMES ASSOCIATED WITH 
UNSTRUCTURED TREATMENT INTERRUPTIONS AMONG HIV-










Objectives: To better understand trends, determinants and consequences of combination 
antiretroviral treatment (cART) interruption and resumption. 
 
Methods: We estimated frequency, determinants and outcomes of treatment interruption 
(TI) and resumption among treatment-naïve HIV-positive individuals in the Canadian 
Observational Cohort (CANOC) collaboration from 2000-2011. Participants resided in 
Canada, were at least 18 years of age, initiated a first antiretroviral regimen comprised of 
at least three agents, had at least 90 days of follow-up and at least one measurement of 
HIV plasma viral load and CD4 cell count within six months of initiating cART. TIs were 
defined as interruptions in cART for a period of at least 90 days and the time to TI 
analysis was limited to patients initiating cART from 2006-2011 to exclude structured 
TIs which were prescribed prior to 2006. 
 
Results: A total of 7,633 CANOC participants initiating cART between 2000 and 2011 
were included in the analyses, of whom 1,860 (24.5%) had at least one TI ≥ 90 days. The 
prevalence of TI in the first calendar year of cART decreased by half over the study 
period. Predictors of a first TI were female sex (adjusted hazard ratio (aHR): 1.59, 95% 
CI: 1.33-1.92), Aboriginal ancestry (aHR: 1.67, 1.27-2.20), a history of injecting drug use 
(aHR: 1.43, CI: 1.09-1.89), hepatitis C antibody seropositivity (aHR: 2.17, CI: 1.68-
2.79), a baseline CD4 cell count above 350 cells/mm3 versus less than 200 cells/mm3 
(aHR: 1.46, CI: 1.17-1.81) and use of zidovudine versus tenofovir in the initial cART 




0.79, CI: 0.73-0.87), higher HIV plasma viral load (log10) (aHR: 0.87, CI: 0.78-0.97) and 
residence in Ontario (aHR: 0.55, CI: 0.43-0.70) or Quebec (aHR: 0.42, CI: 0.31-0.57) 
versus British Columbia (BC). Factors predicting resumption of treatment after a first TI 
included male sex, residence in BC, older age, more recent cART initiation and a CD4 
cell count <200 cells/mm3 at cART initiation (all p<0.05). TIs were associated with 
increased risk of mortality for individuals who subsequently resumed treatment (aHR: 
1.30, CI: (1.06-1.59)) and those who did not resume treatment (aHR: 7.41, CI: (5.73-
9.60)) after adjusting for socio-demographic and clinical factors.  
 
Discussion:  Despite significant improvements in cART since its advent, TIs remain 
relatively common. Strategies to support continuous HIV treatment are needed to 









The expanded use of combination antiretroviral therapy (cART) since 1996 has 
dramatically enhanced the quality of care and the life expectancy of HIV-positive 
individuals [1]. However, sustained optimal use of cART is necessary to ensure 
maximum therapeutic benefits. Incomplete adherence and treatment interruptions (TIs) 
due to treatment fatigue, side effects and cART toxicities [2-4] have therefore emerged as 
major challenges to the full realization of the therapeutic promise of cART.  
Explored as a strategy to reduce cost and cART-related toxicities and improve 
patient quality of life, TIs, whether physician-directed (structured) or patient-initiated 
(unstructured), have been found to promote viral rebound and CD4 cell loss, and more 
importantly, to increase the risk of opportunistic infections and death in observational 
studies and prospective clinical trials [5-14]. As evidence accumulated demonstrating the 
adverse effects of TIs, culminating in the publication of results from the seminal SMART 
trial in 2006, [15] TIs were no longer recommended. However, results from several 
studies indicate that unstructured, patient-elected TIs continue to occur [5, 16, 17]. 
Despite the relatively high frequency of TIs, their determinants and outcomes from 2000 
onwards, a time period often characterized as the era of modern cART [16, 18], and since 
2006 when treatment recommendations were developed that precluded physician-directed 
TIs, are still not well-characterized [16]. 
As the paradigm of “treatment as prevention” and earlier treatment become 
entrenched in contemporary treatment guidelines in North America [19-22] and globally 




Organization’s revised guidelines effectively increase the number of individuals eligible 
for treatment globally by 50% [23], providing urgent impetus to better understand and 
address TIs. 
Thus, we conducted the present study to characterize trends, determinants and 
consequences of treatment interruption and resumption in a setting of universal free 
access to HIV care, including medical and laboratory monitoring as well as cART, in 
Canada. We hypothesized that individuals who are intermittent or episodic users of cART 
(defined here as those with gaps in cART of at least 90 days [5, 10, 24]) are different 
from continuous users. Moreover, we hypothesized that TIs should be less common than 
in previous studies due to improvements in cART profiles over time. We also sought to 
identify which individuals are more likely to reinitiate cART once interrupted, and 






The Canadian Observational Cohort (CANOC) collaboration is a national 
collaboration of eight cohorts situated in three provinces (British Columbia (BC), Quebec 
and Ontario) of antiretroviral-naive HIV-positive individuals initiating cART after 
January 1, 2000. The cohort has been described in more detail elsewhere [25]. Briefly, 
patient eligibility criteria for inclusion into CANOC consists of the following points:  
documented HIV infection, residence in Canada, at least 18 years of age, initiation of a 
first antiretroviral regimen comprised of at least three agents, and at least one 




cART. Patient selection and data extraction are performed locally at the data centers of 
the participating cohort studies. Non-nominal data from each cohort on a predefined set 
of demographic, laboratory, and clinical variables are then pooled and analyzed at the 
Project Data Centre in Vancouver, BC. All participating cohorts have received approval 
from their institutional ethics boards to contribute non-nominal patient-specific data to 
CANOC. In this analysis we excluded individuals with less than 90 days of follow-up to 
account for immortal person-time since these individuals were never at risk for the 
outcome of interest (a TI ≥90 days). The cohort was administratively censored on 
September 1st, 2011. 
 
Outcomes 
The primary outcome in this study was time to first TI, which was defined as an 
interruption in all antiretroviral drugs for a period of at least 90 consecutive days, treated 
as time-varying into an absorbent state (once interrupted always interrupted). However, 
we also separated TIs into two groups for the time to death analysis: those who restarted 
cART after a first TI and those who did not. TIs were identified through prescription 
refill information in BC and through a mixture of clinician reports and pharmacy 
information for sites in Ontario and Quebec. We performed a sensitivity analysis to 
assess the impact of differences in ascertainment of TI on mortality. Time origin for this 
aim was cART initiation and the time axis used was time since cART initiation. A 
secondary outcome was time to resumption of cART, defined as the time from initiation 
of first TI (time origin) to time of treatment resumption for participants who had at least 




analysis identifying factors associated with time to death, which was defined as all-cause 
mortality with time origin at cART initiation. 
 
Exposures 
Additional potential covariates in the models included age at treatment initiation 
(per 10 year increase), sex, Aboriginal ancestry, province, risk category (men who have 
sex with men (MSM), injecting drug use (IDU), heterosexual contact, country of origin 
where HIV is endemic, blood transfusion), and clinical variables such as composition of 
initial cART regimen (nucleoside reverse transcriptase inhibitor (NRTI) backbone and 
third drug in the regimen), hepatitis C antibody seropositivity, and AIDS, HIV plasma 
viral load (log10) and CD4 cell count at cART initiation.  
 
Statistical Analyses 
The chi-squared test was used to determine whether there were significant trends 
over time in the frequency of TIs within one year of cART initiation, among individuals 
with at least 12 months of follow-up from 2000 to 2011. We also examined the 
proportion of CANOC participants with at least 12 months of follow-up who initiated and 
interrupted cART in the same calendar year to demonstrate temporal trends. Patient 
demographical and clinical characteristics at cART initiation were tabulated by treatment 
interruption status and examined for differences using chi-square statistics for categorical 
data and Wilcoxon’s rank sum test for continuous variables. 
Descriptive analyses included Kaplan-Meier curves of time to event by 




points. The log-rank and likelihood ratio tests were used to assess whether the survival 
curves differed by strata of covariates of interest. Univariate Cox proportional hazards 
models were used to examine the relationship of each covariate with the outcome. 
Covariates with p-values less than <0.05 and those deemed to be requisite based on a 
priori information were considered candidates for the multivariable model. Multivariable 
Cox proportional hazards models were constructed to examine factors associated with 
time to first TI. In this analysis, we limited the sample to individuals who initiated 
treatment after January 1st, 2006, to assess only the effect of unstructured TIs and not 
structured TIs, which ceased being prescribed in 2006.  
Cox regression was then used to examine factors associated with time to 
resumption of cART after a first interruption. We also used Cox proportional hazards 
modeling to identify factors associated with time to death from all causes. As the 
assumption of proportional hazards was not met in the time to death analysis, a flexible 
parametric survival model using restricted cubic splines to model the baseline cumulative 
hazard was considered [26]. The proportional hazards assumption was met for the 
remaining two endpoints. Akaike Information Criteria, which balances model goodness 
of fit with the number of parameters, was used to select the models which best fit the data 
for all analyses (lower AIC indicates better fit). Analyses were performed using Stata 





Data were available on 7,633 individuals with at least 90 days of follow-up, of 




(24.5%) interrupted cART over the study period from 2000-2011. Overall, 81% of the 
sample was male, 22% IDU, 67% MSM, and 45% resided in BC. Figure 1 shows the 
decrease in TIs in the first calendar year of treatment among CANOC participants over 
the study period. TIs declined every year from 14% in the year 2000 until 2006, at which 
point the proportion of new initiators interrupting treatment in their first calendar year of 
cART leveled off to approximately 7%. Similarly, TIs in the first year of treatment (based 
on the first 365 days of treatment, data not shown) declined from 11% in 2000 to 8% in 
2009. Of all first TIs, 681 (37%) occurred within the first 6 months after cART initiation; 
290 (16%) occurred between 6-12 months; 351 (19%) between 1-2 years and 538 (29%) 
occurred ≥2 years after cART initiation. In terms of duration of TIs, 604 (33%) 
individuals interrupted for less than six months, 418 (23%) interrupted between six 
months and a year, 285 (15%) of individuals interrupted for one to two years, and 553 
(30%) had TIs longer than two years. Of the 1,860 individuals who interrupted, 1,221 
(16%) interrupted once, 371 (5%) had two interruptions, 158 (2%) had three interruptions 
and 110 (6%) had between four and nine interruptions (Appendix 2). 
Table 1 shows patient demographic and clinical characteristics at cART initiation 
by treatment interruption status. Compared to non-interrupters, treatment interrupters 
were more likely to be female (31% vs. 15%), younger (median age, interquartile range 
(IQR): 38 (32-44) vs. 41 (34-47)), report Aboriginal ancestry (13% vs. 3%), and live in 
BC (64% vs. 39%) (all p<0.001). Behavioral and clinical factors more commonly 
reported by interrupters were a history of IDU (43% vs. 16%), heterosexual transmission 
(33% vs. 25%), hepatitis C antibody seropositivity (46% vs. 18%), use of 




NRTI combinations and use of nevirapine (20 vs. 9%) and an “other” third drug in the 
cART regimen at initiation (all p<0.001). Interrupters were less likely to be men who 
have sex with men (MSM) (25% vs. 38%, p<0.001), originate from a country in which 
HIV is endemic (7% vs. 9%, p<0.001), report AIDS prior to cART (13% vs. 14%, 
p=0.005), use abacavir/lamivudine (10% vs. 16%, p<0.001) or tenofovir/emtricitabine 
(20% vs. 41%, p<0.001) and efavirenz (25% vs. 38%, p<0.001), or atazanivir (16% vs. 
23%) as NRTI combinations and third drugs in the initial cART regimen, respectively. 
 
Time to first TI 
The Cox regression model evaluating factors predicting time to first TI was 
restricted to individuals initiating cART from 2006 onwards and is presented in Table 2. 
Data were available on 4,134 individuals, of whom 626 (15%) had at least one TI over 
9,833 person-years. Mean follow up in this analysis was 2.4 years and median time to 
first TI was 0.60 years (7.2 months). Predictors of a first TI were female sex (adjusted 
hazard ratio (aHR): 1.59, 95% CI: 1.33-1.92), Aboriginal ancestry (aHR: 1.67, CI: 1.27-
2.20), a history of injecting drug use (aHR: 1.43, CI: 1.09-1.89), a hepatitis C antibody 
seropositivity (aHR: 2.17, CI: 1.68-2.79), a baseline CD4 cell count above 350 cells/mm3 
versus less than 200 cells/mm3 (aHR: 1.46, CI: 1.17-1.81) and use of zidovudine versus 
tenofovir in the initial cART regimen (aHR: 2.47, CI: 1.92-3.20). Factors protective 
against TI were older age (aHR: 0.79 per 10 year increase, CI: 0.73-0.87), higher HIV 
plasma viral load (log10) (aHR: 0.87, CI: 0.78-0.97) and residence in Ontario (aHR: 0.55, 
CI: 0.43-0.70) or Quebec (aHR: 0.42, CI: 0.31-0.57) versus BC. There was some 




plasma viral load and CD4 cell count that attenuated both HRs. Figure 2 shows that the 
cumulative probability of interrupting treatment over the study period, which was 0.10 
(CI: 0.09-0.11) after one year on cART. 
 
Time to cART resumption 
Of 1,860 individuals who interrupted therapy, 1,566 (84%) eventually restarted 
cART. Median time to cART resumption was 9.6 months. The Cox regression model 
examining factors predicting resumption of treatment after a first TI, presented in Table 
3, shows that male sex (aHR: 1.22, CI: 1.09-1.37), older age (aHR: 1.10 per 10 year 
increase, CI: 1.04-1.17) and initiation of cART in 2004-2006 (aHR: 1.27, CI: 1.11-1.45) 
or 2007-2011 (aHR: 1.45, CI: 1.24-1.70) versus 2000-2003 were significantly association 
with treatment resumption, while a CD4 cell count 200-349 cells/mm3 (aHR: 0.76, CI: 
0.68-0.85) and greater than 350 cells/mm3 (aHR: 0.43, CI: 0.37-0.50) at cART initiation 
compared to a CD4 cell count less than 200 cells/mm3 and residence in Ontario (aHR: 
0.81, CI: 0.71-0.92) versus BC were associated with less likely resumption of treatment.  
 
Time to death 
Figure 3 shows that cumulative mortality was higher in treatment interrupters who 
did not resume cART in addition to those who did compared to non-interrupters 
(p<0.001, log-rank test). Individuals who did not resume cART were at the highest risk of 
death. The cumulative probability of death at 5 years for non-interrupters was 0.06 (CI: 
0.05-0.07), 0.10 (95% CI: 0.08-0.11) for individuals who interrupted and restarted 




treatment. Table 4 shows unadjusted and adjusted factors predicting time to death. 
Predictors of poorer survival were TI with treatment resumption (aHR: 1.30, CI: 1.06-
2.59), TI with no treatment resumption (aHR: 7.41, CI: 5.73-9.60), female sex (aHR: 
1.32, CI: 1.07-1.62), older age (aHR: 1.56 per 10 year increase, CI: 1.43-1.70), 
Aboriginal ancestry (aHR: 2.25, CI: 1.67-3.03), and a history of IDU (aHR: 2.44, CI: 
1.91-3.12) or unknown IDU history (aHR: 1.83, CI: 1.30-2.58). Clinical factors 
predicting mortality were a baseline diagnosis of AIDS (aHR: 1.54, CI: 1.25-1.91), and a 
NRTI combination in the initial cART regimen of zidovudine/lamiduvine (aHR: 1.64, CI: 
1.21-2.22), stavudine/lamiduvine (aHR: 1.91, CI: 1.37-2.66) or “other” (aHR: 2.05, CI: 
1.48-2.85). Lopinavir as the third drug in the initial cART regimen was also associated 
with higher mortality (aHR: 1.41, CI: 1.09-1.84). Protective factors included residence in 
Ontario (aHR: 0.034, CI: 0.25-0.45) or Quebec (aHR: 0.53, CI: 0.37-0.75) versus BC, 
heterosexual transmission (aHR: 0.54, CI: 0.43-0.67) and a CD4 cell count at cART 
initiation of 200-349 cells/mm3 (aHR: 0.74, CI: 0.60-0.90) or greater than 350 cells/mm3 





Our results demonstrate that the frequency of TI remains relatively high in a 
setting of universal free access to HIV care. TIs continue to be pervasive, with 25% of 
CANOC participants reporting at least one interruption of at least 90 days over the study 
period. However, it is reassuring that the proportion of individuals interrupting cART 




five years. TIs were a significant predictor of all-cause mortality, despite the fact that a 
sizeable majority of individuals who interrupted treatment went on to resume cART. 
While individuals who resumed cART had a lower risk of mortality than those who did 
not resume, even one TI led to a statistically significantly increased risk of death. 
Collectively, these data suggest that there is an urgent need to strengthen communication 
about the need to embrace sustained, lifelong therapy with health providers and patients, 
as a means to optimize the morbidity, mortality and transmission benefits associated with 
the use of cART. 
Improvements in ease of delivery and the side effect profile of cART over time 
appear to have improved the acceptability of these medications for patients. Of note, we 
have documented a marked decline in the proportion of individuals interrupting treatment 
in their first year of treatment over the study period. These results are complementary to 
data from BC which reported a reduction in the prevalence of TIs over the period from 
2000-2006 [5]. While medication side effects were the primary reason for TIs at one time 
[28-31], decreased toxicity associated with cART component drugs has improved the 
tolerability of these medications considerably [31-34]. Consistent with this information, 
we demonstrated that patients who initiate on certain older drugs such as zidovudine have 
a higher risk of interrupting treatment. Additionally, the preponderant use of compact 
once daily fixed dose formulations as preferred first line regimens may have contributed 
to the observed reduction in the proportion of TIs in the first year of treatment in more 
recent years [35], as are 2006 guidelines discontinuing physician-directed TIs.  
Nonetheless, it is concerning that our analysis highlighted a higher risk of TI 




demonstrated by higher CD4 cell counts and lower plasma viral load pre-cART, as has 
been observed in previous studies [16, 24, 36-39]. Additionally, we found that individuals 
with higher CD4 cell counts are less likely to reinitiate therapy after interruption. In this 
context, it is important to emphasize that the current analyses were undertaken using data 
from 2000-2011, during which time cART guidelines were evolving. It is only now, in 
2013, that consensus has been reached regarding the use of cART at CD4 counts ≤500 
cells/mm3 and in selected additional populations regardless of CD4 count (such as 
serodiscordant couples, pregnant women and individuals with co-existing tuberculosis) 
[19-23]. Therefore, it will be important to closely prospectively monitor the incidence 
and determinants of TIs for the foreseeable future, as the number of HIV-positive 
individuals initiating treatment with higher cell counts and lower viral load is likely to 
increase. Assuring that these relatively less immunosuppressed patients are provided with 
the support to maintain continuity of treatment will be imperative to avoid the 
development of drug resistance and worsened prognosis due to TIs as the HIV “treatment 
as prevention” strategy is more widely implemented [32]. Moreover, as many of these 
newly eligible individuals will continue treatment for an extended period of time, 
strategies to counter treatment fatigue are urgently needed.  
Our results suggest that women are at increased risk of interrupting treatment and 
less likely to resume cART following TI. However, this has not been a consistent finding 
across studies [5, 24, 40-43]. Higher risk in women is a phenomenon that may partly be 
due to initiation of cART during pregnancy and subsequent discontinuation of treatment. 
Other possible explanations are that women may report more cART side-effects and 




that women may be unwilling to engage consistently with or prioritize cART if doing so 
may lead to negative perceptions or neglect from others [46]. Consistent with previous 
studies, we found that younger individuals [5, 36, 43, 47], those initiating cART with a 
regimen containing zidovudine [5], and those with hepatitis C co-infection [5, 24] and a 
history of IDU [5, 24, 36] were more likely to interrupt cART. Regional differences were 
also observed, with less risk of TI in Ontario and Quebec compared to BC, a finding 
likely explained by inherent cohort differences. For instance, BC data represents all HIV-
positive individuals on cART across the province while Ontario and Quebec data are 
derived from a selection of specialized clinics; in addition, there are differences in the 
proportion of women, Aboriginal individuals and IDU. 
Lastly, individuals self-reported as having Aboriginal ancestry were at higher risk 
of interrupting treatment. Aboriginal peoples are over-represented in the HIV epidemic in 
Canada, constituting 4% of the population according to the 2011 Canadian census and 
12% of new HIV infections in 2011 [48, 49]. Additional knowledge should be generated 
to understand the reasons for interruption for each of these specific sub-populations and 
specialized services should be designed to support continuous engagement of treatment 
accordingly. 
Resumption of treatment, observed in more than three quarters of individuals who 
interrupted, was more likely in individuals who were males, resided in BC, were older, 
initiated cART more recently and had a CD4 cell count <200 cells/mm3 at treatment 
initiation. Thus, certain predictors of TI were the opposite of predictors of resumption, 
with women and those with higher CD4 cell counts more likely to interrupt and men and 




similar rates of resumption [5, 42, 50]. While the probability of restarting cART is 
relatively high, it is important to note that 15% of individuals never reinitiated treatment 
while under observation. This remains a substantial concern, as these individuals are at 
increased risk of disease progression and premature death, as well as at increased risk of 
transmitting HIV infection. There was some survival benefit conferred to individuals 
resuming cART after TI compared to those who did not reinitiate cART; however, even 
those who resumed cART had a statistically significantly greater risk of mortality. As 
with risk of TI, younger, female individuals initiating cART with higher CD4 cell counts 
should be targeted for additional support to increase the likelihood of resumption after TI. 
Retention in treatment represents a crucial indicator of long-term success for 
people living with HIV. Risk factors for TI identified in this study will aid in identifying 
populations in need of increased support. A number of useful guidelines for managing 
patient retention in care have been developed specifically addressing adherence [51] and 
may also be useful in the context of TIs. The findings presented here may be useful in the 
development of interventions specific to interruptions in treatment; this is an opportune 
area for future research. In particular, more than half of first TIs occurred in the first year 
of treatment, which suggests that new initiators are particularly vulnerable to prolonged 
gaps in engagement and could be targeted for increased monitoring and support.  
 
 Strengths and limitations 
Using data from the largest collaboration of HIV cohorts in Canada to inform 
analyses lent considerable power to analyses. CANOC represents about a quarter of all 




half of those who have initiated on more modern regimens since 2000 [52]. This 
improves the ability to generalize study results to the remainder of the HIV-positive 
population in Canada currently accessing treatment. Unlike many other studies 
examining interruptions in treatment, this study focused on the modern cART period and 
restricted analyses pertaining to predictors of TIs to the period following the 
recommendation not to prescribe TIs, from 2006 onwards. CANOC also enrolled cART-
naïve individuals, which helps isolate the effect of the latest treatment regimens on risk of 
TI. 
This study has several limitations. Ascertainment of TI differs among CANOC 
sites, with some sites recording TIs from medical charts (data from physician, nurses and 
pharmacists), and others using cART prescription refill information as well as 
information from medical charts to identify TIs. We sought to mitigate this potential bias 
by examining differences in time to mortality and time to first TI comparing sites using 
medical charts versus those that used pharmacy and medical charts. No differences were 
observed (data not shown); however, residual confounding may be present that may also 
help explain regional differences in risk of TI. In addition, only the BC cohort recorded 
Aboriginal ancestry, a strong predictor of TI and mortality that may also help account for 
regional difference. We were not able to measure some factors which have been 
associated in other studies with TIs, such as pregnancy, co-morbidities, depression [47, 
53], mental disorders [38], incarceration [54-56], and socioeconomic factors such as 
unstable housing and lack of social supports; these were not captured in the CANOC 
database. As data become available, it will be interesting to observe the impact of these 




contribution to the incidence and prevalence of TIs. Lastly, CANOC includes data from 
only three provinces, and a clinic-based selection bias exists, as included data from BC 
includes the entire sample of people on cART province-wide while data from Ontario and 
Quebec come from a selection of clinics that are mainly HIV-specific. 
In conclusion, our results demonstrate that TIs remain relatively prevalent. This is 
of particular concern given that within our study, TIs continue to be associated with 
increased mortality. Specific strategies may be warranted to decreased the incidence of 
TIs, particularly targeting the most affected groups, such as those who are women, 
younger, of Aboriginal ancestry, IDU, less immunosuppressed at treatment initiation, 
initiate cART with zidovudine/lamivudine, HCV co-infected and have lower HIV plasma 
viral load at cART initiation. Our results uncovered the use of zidovudine versus 
tenofovir in the initial cART regimen as a potentially amenable factor associated with 
TIs. Full implementation of current guidelines, which clearly favor the use of tenofovir 
over zidovudine as a first line agent for cART, should help address this issue. On the 
other hand, the finding that earlier initiation of cART was associated with higher rates of 
TIs is concerning, and merits close prospective monitoring as new guidelines are widely 
and fully implemented. Finally, while it is reassuring to see that over three quarters of the 
observed TIs were time-limited, in view of the serious individual and societal 
consequences of TIs, further targeted efforts are required to maximize resumption of 
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Table 1. Baseline characteristics of 7,633 CANOC participants from 2000-2011 by 












n = 1,860 
p-value 
Sex 7,633    
Male  4,904 (85.0) 1,287 (69.2) <0.001 
Female  869 (15.1) 573 (30.8)  
Median age (IQR)* 7,633 41 (34-47) 38 (32-44) <0.001 
History of IDU† 7,633    
Yes  906 (15.7) 790 (42.5) <0.001 
No  3,477 (60.2) 780 (41.9)  
Unknown  1,390 (24.1) 290 (15.6)  
Province 7,633    
British Columbia  2,276 (39.4) 1,183 (63.6) <0.001 
Ontario  2,135 (37.0) 422 (22.7)  
Quebec  1,362 (23.6) 255 (13.7)  
Aboriginal 7,633    
Yes  172 (3.0) 242 (13.0) <0.001 
No  836 (14.5) 441 (23.7)  
Unknown  4,765 (82.5) 1,177 (63.3)  
Transmission Category     
Men who have sex with men 7,633    
Yes  2,217 (38.4) 457 (24.6) <0.001 
No  1,666 (28.9) 961 (51.7)  
Unknown  1,890 (32.7) 442 (23.8)  
Heterosexual  7,633    
Yes  1,415 (24.5) 607 (32.6) <0.001 
No  2,461 (42.6) 822 (44.2)  
Unknown  1,897 (32.9) 431 (23.2)  
Endemic country of origin  7,633    
Yes  524 (9.1) 128 (6.9) <0.001 
No  3,380 (58.6) 1,302 (70.0)  
Unknown  1,869 (32.4) 430 (23.1)  
Blood transfusion 7,633    
Yes  97 (1.7) 36 (1.9) <0.001 
No  3,731 (64.6) 1,372 (73.8)  
Unknown  1,945 (33.7) 452 (24.3)  
* IQR= interquartile range 
†IDU= injecting drug use 
^pVL=HIV plasma viral load 
**NRTI=nucleoside reverse transcriptase inhibitor  





Table 1 (continued). Characteristics of 7,633 CANOC participants from 2000-2011 












n = 1,860 
p-value 
AIDS prior to cART‡ 7,633    
Yes  791 (13.7) 237 (12.7) 0.005 
No  4,521 (78.3) 1,513 (81.3)  
Unknown  461 (8.0) 110 (5.9)  
Hepatitis C 7,633    
Yes  1,024 (17.7) 851 (45.8) <0.001 
No  4,338 (75.1) 902 (48.5)  
Unknown  411 (7.1) 107 (5.8)  
Median CD4 cell count (IQR) 7,633 210 (120-300) 210 (110-310) 0.004 
Median pVL^ (log10) (IQR) 7,633 4.87 (4.33- 4.84 (4.29-5.00) <0.001 
Year initiated cART 7,633    
2000-2003  1,309 (22.7) 878 (47.2) <0.001 
2004-2006  1,520 (26.3) 526 (28.3)  
2007-2011  2,944 (51.0) 456 (24.5)  
NRTI** combo in baseline     
cART‡ regimen  7,633   <0.001 
Tenofovir/Emtricitabine  2,375 (41.1) 363 (19.5)  
Zidovudine/Lamivudine   1,223 (21.2) 619 (33.3)  
Tenofovir/Lamivudine  458 (7.9) 157 (8.4)  
Abacavir/Lamivudine  905 (15.7) 177 (9.5)  
Stavudine/Lamivudine  395 (6.8) 292 (15.7)  
Other  417 (7.2) 252 (13.6)  
Third drug in baseline     
cART‡ regimen  7,633   <0.001 
Nevirapine   507 (8.8) 371 (20.0)  
Efavirenz  2,193 (38.0) 470 (25.3)  
Lopinavir  1,118 (19.4) 351 (18.9)  
Atazanavir  1,347 (23.3) 296 (15.9)  
Other  608 (10.5) 372 (20.0)  
* IQR= interquartile range 
†IDU= injecting drug use 
^pVL=HIV plasma viral load 
**NRTI=nucleoside reverse transcriptase inhibitor  







Table 2. Factors predicting time to first TI among CANOC participants who 











Female vs. Male 2.78 (2.34-3.13) <0.001 1.59 (1.33-1.92) <0.001 
Age (per 10 year increment) 0.78 (0.71-0.85) <0.001 0.79 (0.73-0.87) <0.001 
Province     
British Columbia 1.00  1.00  
Ontario 0.46 (0.38-0.57) <0.001 0.55 (0.43-0.70) <0.001 
Quebec 0.29 (0.22-0.39) <0.001 0.42 (0.31-0.57) <0.001 
Aboriginal ancestry     
No 1.00  1.00  
Yes 3.12 (2.37-4.11) <0.001 1.69 (1.27-2.20) <0.001 
Unknown 0.59 (0.47-0.73) <0.001 1.01 (0.90-1.28) 0.932 
Transmission group     
History of injecting drug use     
No 1.00  1.00  
Yes 3.92 (3.27-4.70) <0.001 1.43 (1.08-1.89) 0.010 
Unknown 1.14 (0.90-1.45) 0.285 1.02 (0.79-1.31) 0.874 
Men who have sex with men     
No 1.00    
Yes 0.33 (0.27-0.41) <0.001   
Unknown 0.45 (0.37-0.55) <0.001   
Heterosexual     
No 1.00    
Yes 1.38 (1.15-1.68) 0.001   
Unknown 0.79 (0.64-0.98) 0.030   
Endemic country     
No 1.00    
Yes 0.63 (0.44-0.90) 0.011   
Unknown 0.66 (0.54-0.80) <0.001   
Blood transfusion     
No 1.00    
Yes 1.16 (0.64-2.10) 0.636   
Unknown 0.68 (0.56-0.82) <0.001   
**cART: combination antiretroviral therapy 
**NRTI=nucleoside reverse transcriptase inhibitor 






Table 2 (continued). Factors predicting time to first TI among CANOC participants 














AIDS prior to cART*     
No 1.00    
Yes 0.93 (0.71-1.21) 0.597   
Unknown 0.60 (0.39-0.93) 0.023   
Ever diagnosed with Hepatitis C     
No 1.00    
Yes 3.81 (3.22-4.51) <0.001 2.17 (1.68-2.79) <0.001
Unknown 0.99 (0.66-1.48) 0.958 0.75 (0.50-1.12) 0.160 
CD4 cell count at treatment initiation     
<200 cells/mm3 1.00  1.00  
200-349 cells/mm3 0.76 (0.63-0.92) 0.004 0.96 (0.80-1.16) 0.688 
350+ cells/mm3 1.27 (1.02-1.57) 0.030 1.46 (1.17-1.81) <0.001
Plasma viral load at initiation (log10) 0.84 (0.77-0.93) 0.001 0.87 (0.78-0.97) 0.015 
Year initiated cART*     
2006 1.00    
2007 0.84 (0.68-1.04) 0.110   
2008 0.67 (0.53-0.85) 0.001   
2009 0.67 (0.52-0.87) 0.002   
NRTI** combo in baseline cART* 
regimen 
    
Tenofovir/Emtricitabine 1.00  1.00  
Zidovudine/Lamivudine  2.41 (1.89-3.08) <0.001 2.47 (1.92-3.20) <0.001
Tenofovir/Lamivudine 1.26 (0.95-1.67) 0.110 1.32 (1.00-1.75) 0.052 
Abacavir/Lamivudine 0.85 (0.68-1.08) 0.189 1.22 (0.97-1.53) 0.089 
Stavudine/Lamivudine 1.17 (0.48-2.83) 0.729 1.63 (0.67-3.99) 0.282 
Other 1.20 (0.72-2.02) 0.481 1.64 (0.97-2.80) 0.066 
Third drug in baseline cART* 
regimen 
    
Nevirapine  1.00    
Efavirenz 1.63 (0.97-2.71) 0.061   
Lopinavir 2.08 (1.23-3.50) 0.006   
Atazanavir 1.72 (1.03-2.87) 0.037   
Other 3.47 (1.93-6.22) <0.001   
**cART: combination antiretroviral therapy 
**NRTI=nucleoside reverse transcriptase inhibitor 






Table 3. Factors predicting time to resumption of cART after a first TI among 1,860 











Female vs. Male 0.72 (0.65-0.81) <0.001 0.82 (0.73-0.92) 0.001 
Age (per 10 year increment) 1.19 (1.13-1.26) <0.001 1.10 (1.04-1.17) 0.001 
Province     
British Columbia 1.00  1.00  
Ontario 0.70 (0.62-0.80) <0.001 0.81 (0.71-0.92) 0.002 
Quebec 0.77 (0.66-0.89) 0.001 0.88 (0.75-1.03) 0.112 
Aboriginal ancestry     
No 1.00    
Yes 0.92 (0.78-1.09) 0.350   
Unknown 0.78 (0.69-0.87) <0.001   
Transmission group     
History of injecting drug use     
No 1.00    
Yes 1.19 (1.07-1.33) 0.001   
Unknown 0.96 (0.83-1.12) 0.634   
Men who have sex with men     
No 1.00    
Yes 0.96 (0.85-1.09) 0.557   
Unknown 0.97 (0.86-1.09) 0.595   
Heterosexual     
No 1.00    
Yes 0.97 (0.87-1.09) 0.660   
Unknown 0.97 (0.86-1.11) 0.679   
Endemic country     
No 1.00     
Yes 0.66 (0.53-0.81) <0.001   
Unknown 0.95 (0.84-1.07) 0.412   
Blood transfusion     
No 1.00    
Yes 0.90 (0.62-1.29) 0.557   
Unknown 0.95 (0.85-1.07) 0.438   
*cART: combination antiretroviral therapy 
**NRTI=nucleoside reverse transcriptase inhibitor






Table 3 (continued). Factors predicting time to resumption of cART after a first TI 












AIDS prior to cART*     
No 1.00    
Yes 1.45 (1.25-1.67) <0.001   
Unknown 0.87 (0.70-1.08) 0.218   
Ever diagnosed with Hepatitis C     
No 1.00    
Yes 1.12 (1.01-1.24) 0.025   
Unknown 0.76 (0.60-0.97) 0.028   
CD4 cell count at treatment 
initiation 
    
<200 cells/mm3 1.00  1.00  
200-349 cells/mm3 0.75 (0.67-0.84) <0.001 0.76 (0.68-0.85) <0.001
350+ cells/mm3 0.40 (0.35-0.46) <0.001 0.43 (0.37-0.50) <0.001
Year initiated cART*     
2000-2003 1.00  1.00  
2004-2006 1.25 (1.11-1.40) <0.001 1.27 (1.11-1.45) 0.001 
2007-2011 1.42 (1.25-1.62) <0.001 1.45 (1.24-1.70) <0.001
NRTI** combo in baseline cART* 
regimen 
    
Tenofovir/Emtricitabine 1.00    
Zidovudine/Lamivudine  0.55 (0.47-0.64) <0.001   
Tenofovir/Lamivudine 0.93 (0.76-1.13) 0.457   
Abacavir/Lamivudine 0.89 (0.73-1.10) 0.267   
Stavudine/Lamivudine 0.74 (0.62-0.88) <0.001   
Other 0.59 (0.49-0.70) <0.001   
Third drug in baseline cART* 
regimen 
    
Nevirapine  1.00  1.00  
Efavirenz 1.22 (1.05-1.41) 0.011 0.96 (0.81-1.14) 0.640 
Lopinavir 1.27 (1.08-1.49) 0.003 1.16 (0.97-1.38) 0.095 
Atazanavir 1.59 (1.35-1.88) <0.001 1.02 (0.84-1.25) 0.838 
Other 0.83 (0.71-0.97) 0.017 0.88 (0.75-1.04) 0.124 
*cART: combination antiretroviral therapy 
**NRTI=nucleoside reverse transcriptase inhibitor







Table 4. Factors predicting time to death from cART initiation among 7,633 











Interruption type     
No interruption 1.00  1.00  
Interrupted and resumed 
treatment 
1.74 (1.45-2.08) <0.001 1.30 (1.06-1.59) 0.011 
Interrupted and did not 
resume treatment 
7.81 (6.16-9.90) <0.001 7.41 (5.73-9.60) <0.001 
Female vs. Male 1.42 (1.18-1.72) <0.001 1.32 (1.07-1.62) 0.009 
Age (per 10 year increment) 1.44 (1.33-1.56) <0.001 1.56 (1.43-1.70) <0.001 
Province     
British Columbia 1.00  1.00  
Ontario 0.27 (0.21-0.35) <0.001 0.34 (0.25-0.45) <0.001 
Quebec 0.40 (0.31-0.52) <0.001 0.53 (0.37-0.75) <0.001 
Aboriginal ancestry     
No 1.00  1.00  
Yes 2.71 (2.06-3.57) <0.001 2.25 (1.67-3.03) <0.001 
Unknown 0.92 (0.74-1.14) 0.446 1.72 (1.34-2.22) <0.001 
Transmission group     
History of injecting drug use     
No 1.00  1.00  
Yes 3.68 (3.05-4.44) <0.001 2.44 (1.91-3.12) <0.001 
Unknown 2.04 (1.62-2.56) <0.001 1.83 (1.30-2.58) 0.001 
Men who have sex with men     
No 1.00    
Yes 0.42 (0.34-0.52) <0.001   
Unknown 1.00 (0.82-1.21) 0.966   
Heterosexual     
No 1.00  1.00  
Yes 0.56 (0.45-0.70) <0.001 0.54 (0.43-0.67) <0.001 
Unknown 0.89 (0.74-1.07) 0.217 0.94 (0.66-1.36) 0.854 
Endemic country     
No 1.00    
Yes 0.28 (0.17-0.48) <0.001   
Unknown 1.01 (0.84-1.21) 0.936   
Blood transfusion     
No 1.00    
Yes 1.00 (0.55-1.82) 0.994   
Unknown 1.08 (0.91-1.29) 0.382   
*cART: combination antiretroviral therapy 
**NRTI=nucleoside reverse transcriptase inhibitor 






Table 4 (continued). Factors predicting time to death from cART initiation among 





























Ever diagnosed with Hepatitis C     
No 1.00    
Yes 4.28 (3.58-5.11) <0.001   
Unknown 4.17 (3.15-5.51) <0.001   
CD4 cell count at treatment 
initiation 
    
<200 cells/mm3 1.00  1.00  
200-349 cells/mm3 0.61 (0.51-0.74) <0.001 0.74 (0.60-0.90) 0.003 
350+ cells/mm3 0.53 (0.40-0.69) <0.001 0.50 (0.38-0.67) <0.001 
Baseline plasma viral load (log10) 1.33 (1.15-1.54) <0.001   
Year initiated cART*     
2000-2003 1.00    
2004-2006 0.74 (0.61-0.90) 0.003   
2007-2011 0.54 (0.42-0.70) <0.001   
NRTI** combo in baseline cART* 
regimen 
    
Tenofovir/Emtricitabine 1.00  1.00  
Zidovudine/Lamivudine  1.22 (0.93-1.61) 0.152 1.64 (1.21-2.22) 0.002 
Tenofovir/Lamivudine 1.21 (0.84-1.74) 0.314 0.99 (0.68-1.45) 0.978 
Abacavir/Lamivudine 0.97 (0.69-1.40) 0.915 1.16 (0.80-1.67) 0.431 
Stavudine/Lamivudine 2.09 (1.56-2.80) <0.001 1.91 (1.37-2.66) <0.001 
Other 2.23 (1.66-3.00) <0.001 2.05 (1.48-2.85) <0.001 
Third drug in baseline cART* 
regimen 
    
Nevirapine  1.00  1.00  
Efavirenz 0.53 (0.41-0.68) <0.001 0.96 (0.73-1.26) 0.786 
Lopinavir 0.90 (0.71-1.51) 0.415 1.41 (1.09-1.84) 0.010 
Atazanavir 0.63 (0.47-0.83) 0.001 1.16 (0.83-1.62) 0.387 
Other 0.67 (0.52-0.88) 0.003 0.94 (0.72-1.25) 0.688 
*cART: combination antiretroviral therapy 
**NRTI: nucleoside reverse transcriptase inhibitor 






Figure 1. Proportion of CANOC participants with at least 12 months of follow-up 
who interrupted combination antiretroviral therapy (cART) for at least 3 months 















































































Figure 2. Cumulative proportion of CANOC participants interrupting treatment 
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Figure 3. Cumulative mortality of CANOC participants who interrupt and do not 
resume treatment, those who interrupt but do resume treatment and those who do 
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*Curves comparing only treatment interrupters who resumed cART to non-interrupters were also 















The purpose of this dissertation was to evaluate the impact of selected 
demographic, clinical and socio-behavioral characteristics on treatment interruption for 
HIV-positive individuals on combination antiretroviral therapy (cART). The primary 
aims of the research were: a) to assess underlying socio-behavioral factors that are 
associated with treatment interruptions (i.e. distal factors beyond clinical and laboratory 
predictors); b) to identify demographic, laboratory and clinical predictors of a first 
treatment interruption and resumption; and c) assess the impact of treatment interruption 
on HIV disease progression. The first aim (Chapter 2) was completed in the Longitudinal 
Investigations into Supportive and Ancillary health services (LISA) study, using data 
from the province of British Columbia (BC) and the second and third aims (Chapter 3) 
were undertaken using data from the Canadian Observational Cohort (CANOC) 
collaboration, which is the largest HIV treatment cohort in Canada. Chapter 1 described 
the background of the HIV epidemic in Canada and the general literature pertaining to 
unstructured (patient-initiated) and structured (physician-directed) TIs. 
 
4.2. Findings from the Longitudinal Investigations into Supportive and Ancillary 
health services (LISA) study (Chapter 2) 
 
The dissertation used the LISA study, a cross-sectional study of hard-to-reach 
individuals on cART in BC, to examine the association of TIs with factors such as 
housing, drug use, health services utilization and clinical indicators. The LISA study 
enrolled 1,000 HIV-positive individuals over the age of 19 residing in BC between July 
2007 and January 2010 who had ever accessed cART. Using pharmacy records, a TI was 




months preceding or following the study interview. Multivariable logistic regression was 
used to identify factors associated with treatment interruption. 
Results of the LISA study showed that individuals with social vulnerabilities such 
as poor housing stability, unemployment and drug use were more likely to interrupt 
treatment. Individuals dealing with concurrent issues such as a lack of stable housing or 
employment, as well as challenges related to addiction may be unable to prioritize 
maintenance of an HIV treatment regimen, resulting in periods of interruptions of cART 
that may compromise long term prognosis. Thus, establishing safe and stable housing for 
HIV-positive individuals and access to employment is a vital component of the 
constellation of support for patients needed to maintain engagement in treatment. In 
addition, poor adherence in the first year after treatment initiation was associated with 
TIs, suggesting that early inconsistencies in adherence may represent a warning sign of 
future TIs. Individuals who are more likely to embark on lengthy interruptions may 
effectively be identified and targeted for assistance early on in their course of therapy. 
Another valuable set of findings from the LISA study concerned reasons for 
missing cART doses. As the most frequent reason cited, side effects continue to be 
evident in this population; similarly, being too nauseous or sick were commonly reported 
reasons. Logistical issues such as simply forgetting to take pills or to fill a prescription, 
travel, and not having appropriate food or drink were also frequently reported. 
Individuals who interrupted treatment also reported that they did not believe in the 
efficacy of cART or felt well enough that they felt continuing cART was unnecessary, at 
least for the time being. Improved understanding of the reasons for interrupting treatment 




continuing their treatment as prescribed. In addition, these results show that addressing 
socioeconomic barriers to treatment retention is vital for supporting the continuous 
engagement of patients in care. 
 
4.3. Findings from the Canadian Observation Cohort (CANOC) study (Chapter 3) 
 
In Chapter 3 of the dissertation, results from the CANOC study addressing two 
main aims were presented. Firstly, survival models examining factors predicting a first TI 
of at least 90 days and resumption of cART subsequent to TI were evaluated. Secondly, 
survival models were constructed to identify factors associated with mortality. Socio-
demographic covariates in the models included age, sex, Aboriginal ancestry, province 
and risk category (men who have sex with men (MSM), injecting drug use (IDU), 
heterosexual contact, HIV endemic country of origin, blood transfusion). Clinical 
variables such as composition of initial cART regimen (nucleoside (NRTI) backbone and 
third drug in the regimen), hepatitis C antibody seropositivity and HIV plasma viral load 
(log10), AIDS and CD4 cell count at cART initiation were considered. 
Overall, we found that the proportion of individuals interrupting in their first 
calendar year of treatment decreased from 14% to 7% over the study period. Fewer pills 
and the predominance of one pill, once daily fixed dose regimens may be responsible for 
reducing the proportion of TIs in the first year of treatment, as are guidelines 
discontinuing physician-directed TIs from 2006 onwards. Findings from Cox 
proportional hazards regressions models showed that particular groups are at increased 
risk of TIs; specifically, women (aHR: 1.59, 95% CI: 1.33-1.92), younger individuals 




2.20), and IDU (aHR: 1.43, CI: 1.09-1.89).  Clinical factors were also predictive of 
higher risk of TI such as: higher CD4 cell count at treatment initiation (aHR: 1.46, CI: 
1.17-1.81), lower HIV plasma viral load (log10) (aHR: 1.15, CI: 1.03-1.28), cART 
initiation with zidovudine/lamivudine (aHR: 2.47, CI: 1.92-3.20) and hepatitis C antibody 
seropositivity (aHR: 2.17, CI: 1.68-2.79).  
The fact that Aboriginal peoples demonstrated higher risk of TIs is of particular 
concern as they are the fastest growing populations in Canada, and also one of the 
youngest. While treatment responses for Aboriginal peoples on cART are on par with 
non-Aboriginal individuals, individuals reporting Aboriginal ancestry have poorer 
survival [1] and increased vulnerability to other risk factors that may exacerbate their risk 
of TIs in the future [2]. For instance, many Aboriginal people live in small on-reserve 
communities, where seeking access to healthcare can be problematic due to issues related 
to stigma, lack of confidentiality and availability. 
Older cART drugs were associated with TIs, suggesting that certain regimens may 
have higher risk profiles for treatment interruption. This information may be useful for 
physicians identifying an initial regimen for a patient who has been identified as having a 
higher risk of TIs. Moreover, as cART delivery expands globally, that older drugs such as 
zidovudine lead to increased risk of interruption is especially relevant to discussions of 
regimen selection. Results from this study have demonstrated that the first year of 
treatment is of particular importance, with more than half of first interruptions occurring 
within the first year after cART initiation. This is an opportune area to target 
interventions and additional patient support. As cART regimens continue to reduce the 




interrupting treatment may also concomitantly decrease. However, as individuals 
initiating cART with regimens containing relatively tolerable drugs continue to report 
TIs, efforts to reduce TIs must be multi-pronged, addressing both clinical and socio-
behavioral factors that lead to higher risk of interruption. 
Resumption of treatment was observed in more than three quarters of individuals 
who interrupted treatment in CANOC. Individuals more likely to reinitiate cART after a 
first interruption were male, resided in BC, older, initiated cART more recently and had a 
CD4 cell count <200 cells/mm3. Our results indicated that while a majority of participants 
resumed cART, 15% of individuals never reinitiated treatment. These patients are 
unlikely to maintain suppressed pVL during their interruption of cART, increasing their 
own risk of HIV-related morbidity and mortality as well as the likelihood of transmission 
of HIV to others.   
There was some survival benefit conferred by resuming cART after TI compared 
to individuals who did not reinitiate cART; however, even those who resumed cART had 
a statistically significantly greater risk of mortality, suggesting that even one TI may 
compromise an individual’s long-term outcomes. While this study did not have access to 
information on co-morbidities, a possible mechanism leading to increased risk of 
mortality associated with TIs may be due to increased risk of HIV-related complications 
such as cardiovascular and renal disease which are non-reversible. 
 
4.4. Limitations of the study 
 
Participants in the LISA study were high risk and unstable in their lifestyle, which 




undertaken at the British Columbia Centre for Excellence in HIV/AIDS, patients lost to 
the study could be passively followed up through laboratory data. Many of the variables 
being reported in the LISA study were based on self-report. Thus, study data may be 
subject to recall and social desirability biases. In order to mitigate the influence of social 
desirability bias, LISA interviewers who have extensive experience in working with 
injection drug users, MSM and Aboriginal populations in a sensitive manner were 
chosen. 
Ascertainment of TI differs among CANOC sites, with some sites recording TIs 
from medical charts (data from physician, nurses and pharmacists), and others using 
cART prescription refill information as well as information from medical charts to 
identify TIs. We sought to mitigate this potential bias by examining differences in time to 
mortality and time to first TI comparing sites using medical charts versus those that used 
pharmacy and medical records. No differences were observed; however, residual 
confounding may be present that may also help explain regional differences in risk of TI. 
We were not able to measure some factors which have been associated in other studies 
with TIs, such as pregnancy, co-morbidities, depression, mental disorders, incarceration, 
and socioeconomic factors such as unstable housing and lack of social supports; these 
were not captured in the CANOC database. As data become available through linkages 
and other sources, it will be interesting to observe the impact of these latter predictors. 
Future research studying TIs should seek to examine these factors and their 
contribution to the incidence and prevalence of TIs. Lastly, CANOC includes data from 
only three provinces and a clinic-based selection bias also exists, as data from BC 




Quebec come from a selection of clinics that are mainly HIV-specific with highly 
experienced physicians. 
 
4.5. Strengths of the study 
 
The prospective nature of this study has elucidated how the frequency of 
interruptions in treatment changes over time for people living with HIV on cART. We 
have determined what factors predict TIs, to what extent TIs lead to mortality, and what 
factors predict resumption of cART. Using data from the largest collaboration of HIV 
cohorts in Canada to inform analyses lent considerable power to analyses. CANOC 
represents about a quarter of all HIV-positive individuals in the country who are currently 
on cART and approximately half of those who have initiated on more modern regimens 
since 2000, which improves the generalizability of the study results to the remainder of 
the HIV-positive population in Canada currently accessing treatment. Unlike many other 
studies examining interruptions in treatment, this study focused on the modern cART 
period and restricted analyses pertaining to predictors of TIs to the period following the 
recommendation not to prescribe TIs, from 2006 onwards. CANOC also enrolled cART-
naïve individuals, which helps isolate the effect of the latest treatment regimens on risk of 
TI. 
In addition, LISA is one of very few Canadian studies that collect socio-
demographic information such as housing status and availability of social support on 
HIV-positive individuals on treatment; thus, though it is a cross-sectional study, using the 
LISA dataset provides a more complete picture of the social and structural factors that 




through a Community Advisory Board (CAB) composed of members located across BC 
will ensure that results from the study are shared with study participants and policy-
makers, allowing the study to have real-world implications and also giving voice to the 
lived experiences of HIV-positive individuals in Canada.  
 
4.6. Comparative strengths and weaknesses of the two studies 
 
LISA was chosen to undertake an examination of TIs due to the uncommon 
breadth of social and behavioral data collected by the study. A major strength of 
CANOC, meanwhile, is its large sample size derived from cohorts across the country, 
improving the generalizability of results to a greater population; in fact, the HIV 
epidemic in Canada is not dissimilar in scope to epidemics in other North American and 
European contexts, in that it is driven by MSM with rising rates of HIV stemming from 
heterosexual transmission in women. Thus, results from the CANOC cohort may have 
more than simply national relevance. Both LISA and CANOC have unique characteristics 
that combined, offer a diversity of perspectives on the occurrence of TIs in HIV-positive 
individuals on treatment in the modern cART era. 
 
4.7. Directions for future research 
 
There is sparse literature available on interventions designed to address TIs; 
however characteristics of successful interventions designed to improve cART adherence 
may also be applicable in the context of TI reduction. A review by Tuldra and Wu found 




they are comprehensive, longitudinal, and tailored to the person [3]. A systematic review 
by Sandelowski and colleagues examined studies that describe facilitators and barriers to 
antiretroviral adherence as well as interventions designed to address these factors [4]. The 
review found that of the 47 interventions reviewed, 20 targeted one specific problem 
related to non-adherence, such as depression, forgetting to take medication, drug use, 
risky behavior, or poor health literacy. Cognitive-behavioral interventions were the most 
common interventions. The authors concluded that interventions in general were too 
focused on the individual without enough emphasis on targeting larger issues such as 
negative effects on adherence due to societal norms or the health care system [4]. 
Recently published guidelines on improving entry, retention and adherence to 
cART [5] offer a comprehensive review of interventions to improve adherence and make 
recommendations based on the evidence reviewed. Examples of recommendations 
include those relating to cART strategies (once-daily, fixed dose regimens); adherence 
tools for patients (reminder devices, education and counseling); education and counseling 
interventions (one-on-one education and adherence support, group education and 
counseling, multidisciplinary education and counseling, and peer support); and health 
system and service delivery interventions (using nurses and community care, case 
management services and resources to address food insecurity, housing, and 
transportation needs, integration of medication management services into pharmacy 
systems) [5]. Specific recommendations are also made for select groups such as pregnant 
women, those with mental health issues, homeless individuals, youth, incarcerated 




On the other end of the spectrum of adherence, medication persistence represents 
the duration from cART initiation to first instance of TI or substitution of another 
regimen. Interventions from the medication persistence field may also be applicable in 
the context of TIs. However, few interventions have been designed to-date to address 
persistence [6]. Another source for guidance on creating interventions to prevent TIs is 
the literature developed to improve compliance to antibiotic therapy. Counseling and 
patient education were traditionally less successful in this context, though success 
improved when the counseling and patient education were combined with written 
instruction, which could also aid in the context of TIs [7].  
Caveats in adapting recommendations not specifically designed for TIs are that, 
while related, the concepts of adherence, medication persistence and TI are not 
indistinguishable; efforts should be made to understand the differences and implement 
this understanding in the development of interventions for TIs. Measures to address TIs 
and interventions that are developed need to focus not simply on the individual level but 
address structural factors that impede persistence such as unstable living conditions and 
poverty. Lastly, qualitative work will also be useful in deriving reasons for TIs. 
 
4.8. Dissertation Synthesis and Final Reflections 
 
There are 71,300 people currently living with HIV/AIDS in Canada. As 
individuals with HIV live longer, thereby spending more time on treatment, it is 
important to emphasize and facilitate the continuity of engagement in treatment once 
begun. Continuity of treatment is the best approach to maximize the life-extending 




management of HIV. As the paradigm of “treatment as prevention” becomes established 
and treatment earlier in the course of disease is being encouraged, it is important to 
understand how to keep individuals consistently engaged in treatment.  
Moreover, considerably more people will initiate cART after the World Health 
Organization and the International AIDS Society recently expanded the definition of 
patients medically eligible for treatment to include those at any level of CD4 cell count, 
thereby increasing the potential number of individuals who may now initiate cART by 
50% [8, 9]. These recommendations will improve individual outcomes of individuals 
living with HIV and also prevent a number of secondary HIV transmissions. As cART is 
propagated at increasing levels globally, and the impetus to provide treatment earlier in 
the course of HIV infection for individual and public health benefits gains momentum, 
ensuring continuity of treatment becomes even more vital. 
TIs will become increasingly numerous if the frequency of TIs observed in this 
study and others is evident in this group of newly treatment eligible individuals.  Gaps in 
treatment will reduce the effectiveness of the newly established guidelines. The dangers 
associated with TIs, such as increased risk of mortality, the development of resistant 
strains of virus as well as increased risk of HIV transmission will need to be closely 
monitored as treatment is scaled up. 
Results from this dissertation showed that despite universal access to treatment, 
interruptions in treatment among HIV-positive individuals on cART continue to be 
pervasive. Despite the risks associated with TIs, a quarter of individuals in CANOC 
interrupted treatment in the era of modern cART, and 15% of LISA participants 




associated with interruptions in treatment, which caused a pronounced increase in 
mortality in those who interrupted treatment compared to those who maintain continuous 
therapy, even for those who resumed cART. Key findings from this dissertation are that a 
number of clinical factors such as higher CD4 cell count and lower HIV plasma viral load 
at treatment initiation, a history of hepatitis C virus co-infection, and older regimens 
predict TIs. In addition, poor adherence in the first year of treatment was associated with 
TIs, suggesting that early inconsistencies in medication persistence may lead to later 
interruptions in treatment.  
Beyond these clinical findings, results showed that individuals with social 
vulnerabilities such as poor housing stability, unemployment and drug use were more 
likely to report TIs. Addressing both clinical predictors and socioeconomic barriers to 
treatment retention is vital for supporting the continuous engagement of patients in care. 
A finding across both studies that deserves to be highlighted is that individuals who “felt 
well” and those who were less immunosuppressed were more likely to interrupt 
treatment; this result has serious implications in an era of cART expansion. Other factors 
associated with TIs in both LISA and CANOC were injecting drug use and younger age; 
these groups merit special attention in future research investigating interruption. 
Examining resumption of treatment after interruption, results from this 
dissertation show that a large proportion of individuals are likely to reinitiate treatment, 
decreasing but not eliminating their heightened risk of mortality due to interruption. Re-
engaging individuals who have interrupted treatment is another opportune area for further 
research. While interventions specific to prevention of TIs are not yet available, policy-




adherence among HIV-positive individuals. Risk factors identified by this dissertation 
can also be used to inform interventions. The continual improvements in tolerability of 
cART will help reduce the incidence of TIs among the HIV-positive population on 
treatment.  
Collectively, the results presented here support improving patient support and 
education about the harms of interrupting treatment. Moreover, strategies to support 
continuous HIV treatment are needed to maximize the benefits of cART. In 2002, Diane 
Havlir asked, “one is left wondering whether advocating less therapy for this virus 
represents a cutting-edge strategy, a necessary concession, or a shortsighted, premature 
compromise” [10]. This dissertation concludes that TIs are, indeed, a compromise both 
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Smoking (current, ever) 
*Illicit drug use (current, ever) 
Stimulant use (current, ever) 
*Injection drug use (current, ever) 
*Adherence 
Foster home (ever) 
Food security 
*Number of people living with (alone, with many others, on the street) 
Incarceration (ever, last 6 months) 
*Hepatitis C 
*Regimen at interview 
*CD4 count at initiation 
*AIDS at treatment initiation 
HIV plasma viral load at initiation 
Duration of cART use 
*Depression 
Social Support 
Experience of violence (ever, before age 16) 
*Overall health rating 
HIV limits activities 
Stigma 





Men who have sex with men 
Sex trade 
Reasons for missing cART doses 
HIV diagnosis year 














0 5,7330 75.63 
1 1,221 16.00 
2 371 4.86 
3 158 2.07 
4 64 0.84 
5 21 0.28 
6 14 0.18 
7 5 0.07 
8 3 0.04 
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